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!Abstract 
A shortlist of candidate tumour endothelial markers was generated by Microarray 
comparison of differential gene expression between multiple patient-matched 
colorectal cancer and normal colon samples. This list was narrowed through a 
process of literature review, real-time quantitative polymerase chain reaction and 
immunohistochemistry. GRIN2D, a subunit of a glutamate dependent, ionotropic 
NMDA receptor, and facilitator of cellular calcium influx, previously found in neuronal 
tissues, was identified as the most promising target from this shortlist.  
Through siRNA knockdown and analysis in in vitro models of angiogenesis, it has 
been demonstrated that a decrease in GRIN2D expression significantly decreases 
cellular migration, communication and chemotaxis, without adversely affecting cell 
viability or proliferation in HUVEC.  
Vaccination with a murine GRIN2D-Fc fusion protein in combination with Freund’s 
adjuvant stimulated a specific immune response to this self-antigen, by breaking 
immune tolerance. The resulting increase in specific IgG1 antibody titers, indicative 
of Th2 T-cell response, resulted in a significant reduction in physiological 
angiogenesis in the subcutaneous sponge assay, and a significant decrease in 
colorectal tumour growth in a murine subcutaneous CT26 tumour model. 
GRIN2D represents a novel tumour endothelial marker in colorectal cancer. A 
hypothesised mechanism for the observed effects is an inhibition of endothelial 
calcium influx, leading to decreased angiogenic potential in tumour endothelial cells. 
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CHAPTER ONE 
 
INTRODUCTION 
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1.1 COLORECTAL CANCER 
Colorectal Cancer (CRC) represents the third most commonly diagnosed malignancy 
in humans worldwide, with 33,218 cases diagnosed in 2010 in England alone(1). The 
mainstay of curative treatment relies upon a histologically clear resection margin at 
surgery(2), and the long-term absence of metastatic spread.  Around 80% of surgical 
resections for CRC result in complete local microscopic clearance of disease, but of 
these, 50% will relapse to metastatic disease, due to micrometastases which were 
present at the time of original resection(3). This premise is the basis for routine 
adjuvant treatment of poor prognostic groups (Dukes stage C/D) with systemic 
therapies. Chemotherapeutic agents have been in established use as an adjuvant 
treatment in CRC for over 50 years(4), but despite introduction of new agents, and 
the use of monoclonal antibodies, presentation with macroscopic or microscopic 
metastatic disease still carries a poor prognosis(5). Targeting of the vasculature of 
CRCs has been shown to be of interest(6), with anti-angiogenic agents licensed for 
advanced disease. However, vascular targeting in the form of a targeted specific 
immunotherapy in CRC has not been described. This thesis describes the process of 
identification of an endothelial specific target in CRC, the development of a tumour-
vessel specific vaccine, and the investigation of its effects in in vivo murine models of 
angiogenesis and tumour growth. 
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1.1.1 Histology of Colorectal Cancer 
More than 90% of CRCs are adenocarcinomas, originating from the glandular 
epithelium of the colon. Identification of malignancy within glandular epithelium is 
confirmed by the presence of invasion beyond the mucosa into the submucosa, and 
that of a desmoplastic, or fibrous, reaction in the surrounding stroma secondary to 
tumour infiltration(7). 
1.1.2 The Adenoma – Carcinoma Sequence 
The development of sporadic CRC is associated with a multi-step series of genetic 
changes that promote proliferation of the epithelium(8). The progression from normal 
epithelium, through dysplasia, and eventual progression to invasive malignancy is 
governed by a series of genetic mutations via a consistent pathway. 
Figure 1.1 – The Adenoma-Carcinoma Sequence. APC – adenomatous 
polyposis coli; k-RAS – Kirsten Rat Sarcoma oncogene; DCC – Deleted in 
Colorectal Cancer. 
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These mutations are thought to occur via two pathways – chromosomal instability 
and microsatellite instability(8). Chromosomal instability describes alterations in 
chromosome complement (aneuploidy) or deletion or amplification of specific, 
detectable loci, where microsatellite instability describes the acquisition of errors in 
DNA mismatch repair. 
1.1.3 Staging and Prognosis of Colorectal Cancer 
The prognosis of patients with colorectal cancer depends upon the extent of 
locoregional and distant spread. The staging system for colorectal cancer, originally 
described by Cuthbert Dukes in 1958(9), has subsequently been modified to include 
the presence of distant metastasis. It now forms the basis for treatment planning in 
the United Kingdom.  
Dukes Stage Tumour Extent Prevalence 1st Line 
Treatment 
5-year 
Survival 
A Tumour 
extends into but 
not beyond 
muscularis 
mucosa 
13.2% Surgery 93.2% 
B Tumour 
penetrates into 
subserosa and 
beyond, 
including 
invasion into 
other organs 
37.3% Surgery 77.0% 
C Involvement of 
local lymph 
nodes. 
35.9% Surgery + 
Adjunctive 
Treatment 
47.7% 
D Any Distant 
Metastasis 
14.0% Adjunctive 
Treatment +/- 
Surgery 
6.6% 
     
Table 1 – Pathology, Prevalence, Standard Treatment and Survival by Dukes’ 
Stage.  Data is adapted from Cancer Research UK (CRUK)(10):  
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While surgical management can be curative in early stage tumours, once there is 
evidence of loco-regional spread, relative survival falls rapidly. Current management 
initiatives such as the bowel cancer screening programme in the UK are aimed at 
identifying tumours at an early or pre-malignant stage. An alternative route for 
improvement of patient prognosis is the development of novel adjuvant treatments 
with the aim of down-staging disease, and decreasing the effects of micrometastases 
already present in the circulation or distant organs, or eliminating them entirely. 
 
1.1.4 Treatment of Colorectal Cancer 
1.1.4.1 Surgical Treatment of Primary Colorectal Cancer  
Successful surgical resection of colorectal cancer depends upon an en bloc excision 
of the tumour and its draining lymph nodes, while maintaining optimal blood supply to 
the remaining bowel. Classically this has been performed via a large incision in the 
abdominal wall, or laparotomy, but more recently, advances in technique have 
enabled successful bowel resection by keyhole, or laparoscopic(11), methods, 
including the use of robotic resection(12).  
 
1.1.4.2 Chemotherapy for Colorectal Cancer 
Chemotherapeutic agents broadly work by interrupting the cell cycle, thereby limiting 
mitosis and hence tumour growth. The majority achieve this by directly inducing DNA 
damage, or by interfering with intracellular mechanisms that limit the process(13). 
Chemotherapy has been the primary adjuvant treatment in patients with CRC for 
over 30 years. It is efficacious in terms of increasing longevity and quality of life in 
patients with Dukes stage C and D disease. In Dukes C disease it has been shown to 
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increase five-year disease-free survival by 8-13%(14). There is also evidence for its 
neoadjuvant use in decreasing tumour burden prior to surgical resection in locally 
advanced cases(15). However, there is only limited evidence of benefit in so-called 
early stage disease, in the absence of lymph node involvement at the time of 
diagnosis. The National Institute of Health and Care Excellence (NICE) in the UK, 
only recommends its use in ‘high-risk’ Dukes B disease – those tumours with 
histological evidence of lymphovascular invasion, peritoneal tumour involvement or 
evidence of pre- or peri-operative perforation(16,17). 
 
The first agent successfully used in CRC was 5-Fluorouracil (5FU), an antimetabolite 
agent which inhibits the action of thymidylate synthase, thereby blocking DNA 
synthesis(18). It remains the agent of choice in first line treatment, in its oral form, 
capecitabine, either alone or in combination with oxaliplatin and folinic acid(17). The 
intravenous regimen (utilising 5FU) is known as FOLFOX, with its oral counterpart 
(utilising capecitabine) known as CAPOX. These are the treatment regimens of 
choice in advanced or metastatic disease, with irinotecan (FOLFIRI) reserved for 
refractory disease(19). 
 
1.1.4.3 Radiotherapy for Colorectal Cancer 
Radiotherapy works by the direct damage of cellular DNA, leading to apoptosis, and 
a large inflammatory response. Because of these actions, and the lack of tissue 
specificity involved in this treatment modality, radiotherapy has to be carefully 
planned and targeted to minimise exposure of surrounding non-malignant tissues to 
damaging ionising radiation. In colorectal cancer, pre-operative radiotherapy is 
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reserved for low rectal tumours where the circumferential resection margin (CRM) for 
surgery is compromised by the tumour. This situation risks leaving malignant cells 
behind following resection, so the cytotoxic effect of radiotherapy is used to downsize 
the tumour, in combination with chemotherapy. Post-operatively, radiotherapy can be 
utilised in both colonic and rectal malignancy under the following circumstances(20): 
i. Where there is involvement of the surgical resection margin 
ii. Where there is invasion of the peritoneal or abdominal wall identified either pre- or 
peri-operatively. 
iii. Where there are post-operative findings of High Risk Dukes B, or Dukes C 
disease in disease that was ‘under staged’ pre-operatively, and therefore did not 
undergo pre-operative chemoradiotherapy. 
 
1.1.4.4 Immunotherapy for Colorectal Cancer 
    The development of antigen-specific immunotherapies relies upon identification of 
a specific, over-expressed antigen in the malignancy of interest (21), and can be 
divided into passive and active immunotherapies.  
    Passive immunotherapy in the form of monoclonal antibodies (MAb) has gained 
widespread interest in the last 20 years, with effective treatment available in Renal 
Cell Carcinoma (Anti-VEGF-A MAb, Avastin®, bevacizumab), Breast cancer (Anti-
Her2 MAb, Herceptin®, trastuzumab) and haematological malignancies (Anti-CD20 
MAb, MabThera®, Rituximab). However, primary colorectal cancer remains a difficult 
target for immune therapies(22), with no currently licenced immunotherapies for the 
Dukes A-C disease.  Cetuximab, bevacizumab, and a third monoclonal antibody, 
panitumumab, are also currently licenced for use in the treatment of advanced 
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colorectal cancer, although evidence of benefit is limited, with response rates below 
5% when used as a monotherapy (23). Improved outcomes are found when these 
compounds are used in combination with established chemotherapy regimens. This 
lack of response has also been coupled with observations in animal models that an 
initial stabilization in tumour size is then followed by a rapid growth of a more 
aggressive tumour, as a result of the tumour acquiring functional ways to avoid 
VEGF in angiogenesis, as demonstrated in a mouse model of pancreatic 
neuroendocrine tumour(24). There are also surgical considerations becoming 
apparent with bevacizumab, with a recent meta-analysis identifying prior treatment 
being an independent risk factor for anastomotic leak following resection(25). 
 
Active specific immunotherapy in CRC is discussed in section 1.4 
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1.2 ANGIOGENESIS 
The role of the vascular network is to both deliver nutrients and substrates to the 
tissues, and to conduct metabolic by-products to end organs for deactivation and 
excretion. Angiogenesis describes the generation of new blood vessels from the pre-
existing vascular network(26). It is preceded by vasculogenesis, which lays down the 
original vascular network during embryonic development through differentiation of 
angioblasts. Physiologically, angiogenesis occurs during wound healing, 
menstruation and pregnancy, with the process also being involved in numerous 
pathological conditions, the most notable of which is malignancy(27). 
 
1.2.1 Physiological Angiogenesis 
Angiogenesis can be divided into sprouting and non-sprouting angiogenesis, the 
latter of which is also known as intussusception(26).  
Sprouting angiogenesis is the longest lived, and hence considered the conventional 
pathway of angiogenesis. It occurs both in the yolk sac, and in the embryo, and is 
characterised by the disruption of the basement membrane of existing vasculature by 
a group of enzymes produced by activated endothelial cells - the matrix 
metalloproteinases (MMPs) and their inhibitors. Following the activation of cell 
surface receptors on endothelial cells by substances such as VEGF(28), the cell 
membrane is destabilised and this leads to formation of filopodia.  These cells in turn 
secrete MMPs, and dissolve the basement membrane supporting the existing 
vasculature, causing proliferation of endothelial cells towards the source of the 
angiogenic stimulus. This results in an increase in both the number of blood vessels, 
and an increase in the total endothelial cell number. 
!"+!
Intussusceptive angiogenesis was first described in 1986(29), and is an intravascular 
phenomenon resulting from the formation of pillars into the vessel lumen, which 
subsequently leads to establishment of an endothelial junction between two newly 
divided vessels(30). This method can increase the surface area of a capillary network 
without increasing the underlying number of endothelial cells, making it especially 
important during embryological development where there are a limited number of 
endothelial cells available(31). 
 
Figure 1.2 – The Contrast Between Sprouting and Intussusceptive 
Angiogenesis. 
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1.2.2 Tumour Angiogenesis 
While there is significant variation in the doubling time for capillary endothelium in 
physiological tissues, ranging from 47 to 20 000 days, this is considerably shorter, at 
2-13 days, in tumour vasculature(32). This indicates that angiogenesis is a tightly 
controlled process in normal physiology, which has been overcome in the growth of 
malignant tumours. 
Below the volume of around 2 mm3, tumours can absorb the necessary nutrients 
from the surround tissues by diffusion(33). However, just as in normal physiological 
situations, as tumours grow their metabolic demand increases, creating relative 
hypoxia. This results in a period of dormant growth, as the immature tumour lacks the 
ability to stimulate angiogenesis. Future mutations result in the production of 
substances such as VEGF, IL-8 and bFGF which promote the formation of new blood 
vessels, thereby perpetuating tumour growth, and allowing the potential for 
metastasis(33-35). This genetic change forms part of the ‘angiogenic switch’, which 
describes a tumours’ change to an angiogenic phenotype. This switch has been 
attributed to(36): 
i. The capability of tumour to recruit their own blood supply 
ii. Recruitment of endothelial stem cells towards the vascular bed of tumours 
iii. Amplification of the angiogenic signal by stromal cells such as macrophages, 
pericytes and vascular smooth muscle cells.  
iv. Vessel co-option, whereby tumour cells cause endothelial cell apoptosis and 
induce neovascular sprouts from neighbouring vessels within normal tissues. 
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 It has subsequently been shown that targeting of the process of tumour 
angiogenesis can starve the tumour of substrates, and cause regression. This has 
the theoretical advantage over the targeting of tumour cells that endothelial cells are 
relatively genetically stable and homogenous, rather than being prone to frequent 
mutations(37), as is the case with tumour cells. 
 
  
Figure 1.3 – Tumour-Induced Angiogenesis. Taken from (38), with permission 
from Nature Publishing Group. 
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1.2.3 Anti-angiogenic Therapies 
Anti-angiogenic agents act by preventing the generation of new blood vessels, and 
consequently have a cytostatic effect, resulting in a stabilisation of tumour size(39). 
These agents aim to return a tumour to a status of dormancy, and are therefore a 
useful adjunct to chemotherapy regimens, radiotherapy or surgery. Many 
chemotherapeutic agents have both a direct cytotoxic and an anti-angiogenic effect. 
Broadly, a compound is considered to be primarily anti-angiogenic if its anti-
angiogenic action occurs at a lower concentration than its cytotoxic threshold(36). 
Three categories of anti-angiogenic agents have been proposed(40): 
i. Direct anti-angiogenics, which act by the targeting of either the endothelial cells or 
their functions, which are involved in angiogenesis (proliferation, migration or the 
formulation of new blood vessels (e.g. angiostatin, thalidomide). 
ii. Indirect antiangiogenic drugs which impair the production of angiogenic factors by 
the tumour cells, and those cells within the tumour microenvironment, or to 
interfere with resultant extracellular processes (e.g. cetuximab, gefitinib) 
iii. Mixed anti-angiogenic drugs that may be able to interfere with both endothelial 
and tumour cells (e.g. bevacizumab). 
 
1.2.4 Vascular Targeting Therapies 
These methods aim to disrupt or destroy existing vasculature, thereby starving the 
tumour of oxygen and metabolic substrates. Tumours are much more dependent on 
their microvasculature than physiologically normal tissues, with potentially hundreds 
of cell layers being dependent on a single endothelial cell. As a consequence, direct 
vascular disruption can result in significant, rapid tumour apoptosis and acute 
!14!
regression(41).  These methods can be mechanical, such as the embolization of 
isolated liver metastases(42), or can be pharmacological. This latter group can be 
divided into three classes(39): 
i. Ligand-directed vascular targeting agents 
These agents rely upon the identification of a target that is sufficiently upregulated 
on tumour-associated endothelium compared to that of the normal vasculature for 
there to be specific action within the tumour, without causing significant systemic 
toxicity. Studies have focused upon antibodies to such targets which are then 
conjugated to directly toxic or pro-thrombotic compounds(43), termed antibody-
drug conjugates. 
ii. Small-molecule vascular targeting agents 
This group of agents is analogous to tubulin-binding agents (e.g. 
combretastatin(44)). The small molecules bind to the tubulin cytoskeleton of 
endothelial cells and cause a conformational change. This exposes the basement 
membrane, resulting in activation of the coagulation cascade.  
iii. Cationic liposome-based vascular targeting therapy. 
Cationic liposomes selectively target activated tumour endothelium, as opposed 
to neutral and anionic liposomes which extravasate into the tumour 
interstitium(45). These liposomes can then be used to encapsulate cytotoxic 
compounds (e.g. paclitaxel), and thereby mediate concentrated vascular-targeted 
effects. 
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1.3 VASCULAR ENDOTHELIUM 
Vascular endothelium forms the lining of all vascular and lymphoid vessels within the 
body. Endothelium has specialised roles including a role in angiogenesis, but also as 
an endocrine organ, having functions in regulating blood pressure, inflammation and 
coagulation(46).  This thin monolayer controls the transport of proteins solutes and 
gases across the blood vessel wall(47). It is supported by a basement membrane, 
and in the case of capillaries, is partially covered by pericytes. In larger veins and 
arteries, vascular smooth muscle cells and collagenous connective tissue surround 
this layer. They are generally considered to be quiescent in normal physiology, but 
their abnormal activation, or errors in their inactivation have been shown to be 
responsible for a variety of vascular disorders(48). 
It has recently been appreciated that there is significant interdependence between 
endothelial cells, and their surrounding microenvironment, with the endothelial 
transcriptome influenced by that of nearby tumour cells(49).  
 
 
1.3.1 Isolation of Endothelial Cells  
In order to perform endothelial specific assays, it is important to be able to effectively 
isolate endothelial cells from surrounding tissues. The initial reports of endothelial cell 
isolation and culture date back to the 1970’s(50,51), but conventional tissue culture 
techniques have been found to significantly affect the transcriptome of cultured 
endothelial cells, due to lack of flow, and acidic stress(52). As a result, it is important 
that in vivo samples of tissue for endothelial cell isolation and assays to determine 
genetic expression profile are obtained expediently.  
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1.3.2 Tumour Endothelial Markers (TEMs)  
There is significant evidence that capillaries within tumours differ in terms of their 
structure, integrity and flow characteristics compared to that of surrounding normal 
tissue(53). As a consequence, the genetic profile, and hence protein expression on 
the endothelial cell surface of tumour-associated endothelium differs significantly to 
that within normal tissues. This difference in expression can be exploited to identify 
potential therapeutic targets.  
The work of St. Croix published in 2000 contained the first reference to tumour 
endothelial markers (TEMs)(53). Within this work, endothelial cells were extracted 
from CRC tumour samples, and neighbouring normal colon, followed by RNA 
extraction and SAGE (Serial Analysis of Gene Expression) to identify and quantify 
consistently upregulated genes. The resultant identified markers were termed TEM1-
10, and have formed the basis of many pre-clinical papers. However, despite 
considerable interest in these targets(54), clinical data has been lacking.  
 
1.3.3 GRIN2D 
GRIN2D (Glutamate Receptor, Ionotropic, N-Methyl D-aspartate (NMDA) receptor 
subunit 2D), also known as the NMDA receptor subunit 2D (NMDAR2D/NR2D), and 
NMDA receptor subunit 2ε, is a subunit of a glutamate dependent calcium channel, 
conventionally found in neuronal tissues. Chromosomally, GRIN2D is localized within 
the region 19q13.1–qter(55). Each NMDA Receptor is comprised of two NR1 
subunits, and two NR2 or NR3 subunits. These heterotetramers are transmembrane 
proteins, with an intracellular C-terminus and an extracellular N-Terminus (Figure 
1.4). NR2 subunits both provide the glutamate-binding sites in the NMDA receptor 
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complex(56), and also modify the channel properties, particularly in terms of ion 
flux(57,58). 
 
 
Figure 1.4 – The Structure of Ionotropic NMDA Receptors. GLU – Glutamate 
binding Site. Taken from (59), with permission from Nature Publishing Group. 
 
The NMDA receptors are involved in long-term potentiation within the central nervous 
system – a process that is intimately involved in the processes of learning and 
memory(60), as well as synaptic plasticity(61). GRIN2D is most highly expressed in 
the embryonic and early neonatal rodent brain, with expression declining, and 
becoming more focally expressed in the brain stem and cerebellum(60) with 
progressing age. These initial findings of central nervous system expression in rats 
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have since been corroborated in human studies(62). Subsequently, NMDA 
Receptors have been identified within the enteric nervous system, and are implicated 
in the modulation of visceral sensitivity and pain, where activation of peripheral 
NMDA receptors in colonic tissue sections in rats has shown to cause calcium-
dependent release of pro-inflammatory neuropeptides(63). These early animal 
studies have laid the foundation for studies which have shown the association 
between the up-regulation of NMDA receptors and the presence of visceral pain in 
patients with Ulcerative Colitis(64). This influx of calcium, regulated by NMDA 
receptors, has been shown to protect against apoptosis(65), and this, alongside its 
association with colonic inflammation offers logical reasons for its presence as a 
tumour endothelial protein in CRC. Indeed, GRIN2D has previously been shown to 
be ubiquitously present within human tumour cell lines in vitro, including the HT29 
colorectal adenocarcinoma line(66). 
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1.4 VACCINATION 
Vaccination was developed as a method of inducing protection against 
communicable diseases in the late 18th Century. The work of Edward Jenner 
modified the practice of variolation, which involved the direct inoculation of the 
ground scabs of smallpox sores into wounds to offer protection(67). His work, 
published in 1798, described the inoculation of fluid from cow-pox lesions into 23 
patients, with consequent protection offered against smallpox in the medium 
term(68). This resultant protection afforded by the exposure of a patient to a less 
pathogenic form of a contagion has formed the basis of all future vaccine 
development, whether these vaccines be directed against a communicable disease 
or a malignancy, as is now the case with the human papilloma virus in cervical 
cancer(69). 
 
1.4.1 Vaccine Design  
The development of a vaccine essentially relies upon the identification of a target that 
is specific to the intended target pathology (the antigen), and a compound to induce 
an immune response (the adjuvant)(70). 
Optimisation of the antigen by selection of only specific areas of its structure is 
necessary to prevent autoimmune responses, to target immune responses against 
particular strains or forms of the pathogen, and to prevent predominant immune 
responses to areas of the pathogen prone to genetic (or antigenic) drift. However, the 
selected peptide must cover enough of the target protein to prevent vaccine inactivity 
due to clonal variability(70). 
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The use of an adjuvant to induce immune response is often necessary, as many 
epitopes lack the molecular cues necessary to be innately immunogenic. This is the 
case when self-antigens are the targets of interest. Within humans, the only 
approved adjuvant is Alum, as many of the bacterial-derived compounds are 
toxic(71). However, these bacterial compounds are widely used in animal studies. 
Some of the more recent vaccines for human use have been engineered within 
specific delivery systems. These have been developed, as some antigens are broken 
down within the circulation prior to presentation to immune reactive cell types. 
Examples of these would be enclosure of the vaccine within recombinant viral 
vectors or conjugation to antibodies which are specific to immune reactive cells, such 
as Clec-9A(72). 
 
1.4.2 The Immune Response to Vaccination 
The first requirement of a vaccine is for it to trigger an immune reaction mediated by 
the cells of the innate immune system(73). Following administration of a vaccine, 
circulating dendritic cells are recruited to the site of inoculation, and undergo 
maturation. This maturation stimulates the modulation of specific cell surface 
molecules such as inflammatory cytokines and chemokines(74). Locally, this 
promotes an inflammatory microenvironment with extravasation and attraction of 
monocytes, granulocytes and natural killer cells. Systemically, this maturation causes 
migration of dendritic cells towards secondary lymph nodes. It is at this site where the 
induction of T- and B- lymphocyte response occurs(75).  
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B-Cell Responses 
Within the lymph nodes, B-cells are activated by the presence of vaccine antigens, 
and move towards the marginal zone, where they are exposed to activated dendritic 
cells, and activated T-helper cells. This leads to the differentiation of B-cells into 
plasma cells within germinal centres, which produce large amounts of antibody to the 
vaccine antigen. In rodents, Th1 T-cells promote a switch towards IgG2a, whereas 
Th2 T-cells support the generation of IgG1 and IgE (via IL-4) and IgG2b and IgG3 
(via TGF-β)(76). This differentiation is less predominant in humans, where the IgG1 
subtype predominates regardless of the helper T-cell subtype. This portion of the 
immune response lasts only for around 28 days. However, a fraction of plasma cells 
that differentiated into germinal centres acquire the capacity to migrate towards long-
term survival niches mostly located within the bone marrow, from where they may 
produce vaccine-derived antibodies for extended periods. These are then termed 
memory B-Cells. An additional exposure to the antigen, or a ‘booster’ vaccination will 
reactivate these memory cells, and lead to a longer, more pronounced immune 
response(77) (Figure 1.5). 
 
T-Cell Responses 
Activated dendritic cells display major histocompatibility complex (MHC) proteins on 
their surface, and are transported to the peripheral zone of lymph nodes. CD4+ T-
Cells, which are activated by MHC Class II proteins, proceed down one of two 
pathways with differentiation into either Th1-type or Th2-type cells.  Th1-cells 
produce IFN-γ and TNF-α, leading to the elimination of intracellular pathogens both 
via cytokine responses and through their support of macrophage activation and CD8+ 
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T-cell differentiation (78). Th2-type CD4+ T cells produce IL-4, IL-5 and IL-13 which 
are directly implicated in the defense against extracellular pathogens such as 
helminths(79). 
The ongoing immune response beyond around 28 days relies upon T-cell memory. 
The degree to which a T-cell memory response is maintained depends predominantly 
upon the amount of antigen present during initial vaccination(80). The degree of 
future immune response also depends upon whether there is predominantly an effect 
via effector memory B-cells, which are mobile throughout the non-lymphoid organs, 
or central memory B-cells, which traffic through the spleen and lymph nodes. Effector 
memory cells have a high cytotoxic capacity, so can act swiftly, but lack the 
proliferative potential of central memory cells(81). 
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Figure 1.5 - Correlation of Antibody Titers to the Various Phases of the Vaccine 
Response. An initial antigen exposure stimulates an extra-follicular response [1]. 
This results in the rapid production of low concentrations of IgG antibody. As B-cells 
proliferate in germinal centers, with differentiation into plasma cells, IgG antibody 
levels increase to a peak value [2]. This is usually reached 4 weeks after 
immunisation. The short life plasma cells results in a rapid fall in antibody titers [3], 
which eventually return to baseline levels [4]. In secondary immune responses, a 
secondary exposure to an antigen reactivates memory cells, resulting in a rapid 
increase of IgG antibody titer [5]. ‘Short-lived’ plasma cells maintain peak antibody 
levels [6] for the first few weeks, after which titers decline with the same rapid kinetics 
as that which follows primary immunisation [7]. ‘Long-lived’ plasma cells, which have 
reached survival niches, continue to produce antigen-specific antibodies, which then 
decline over a slower course [8]. Taken from (75), with permission from Elsevier. 
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1.4.3 Therapeutic Vaccination in Colorectal Cancer. 
Active specific immunotherapy in the form of a vaccination has developed as a new 
route of targeting both primary tumours and potentially unidentified distant 
micrometastases in CRC(22).  
Clinically, it has been stated that endothelial cell vaccines may be beneficial in 
subgroups of patients following colorectal resection(22), and early studies in a mouse 
model of metastatic CRC have yielded encouraging results(82), with a detectable 
immune response to injected hepatic sinusoidal cells – a highly angiogenic 
endothelial cell line. Indeed, Vermorken et al. describe successful vaccination using 
an autologous tumour cell-BCG conjugate vaccine with excellent results in Dukes B 
Cancers (83). This had led to the development of the OncoVax™ tumour vaccine. 
While this has shown good results in a Phase III randomised controlled trial (84), it is 
patient specific, and therefore requires individual tumour profiling and generation of 
an individualised vaccine. Economically, this is not ideal, and the search for a more 
generaliseable vaccine is ongoing. Early experience with vaccination of human 
umbilical vein endothelial cells (HUVEC) in patients with metastatic CRC 
demonstrated little response(85).  Since these initial targets were studied, a large 
number of tumour-specific antigens have been identified in GI malignancies, the most 
frequently targeted of which are CEA and Ep-CAM (Epithelial cell-adhesion 
molecule)(21). Early clinical results of a CEA-based vaccine within a phase II clinical 
trial in patients with metastatic CRC, have indicated an objective clinical response in 
40% of enrolled patients when combined with a chemotherapeutic regime(86). 
A further therapeutic vaccine known as TroVax® has also undergone phase-I and 
early phase-II trials in metastatic colorectal cancer(87). This vaccine is targeted 
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against a pan-cancer tumour target, 5T4, and has demonstrated a stimulation of 
immune response in these early clinical trials, with some evidence of disease 
response in those patients demonstrating a 5T4-specific immune response. 
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1.5 HYPOTHESIS, AIMS AND OBJECTIVES 
 
1.5.1 Hypothesis 
That a putative TEM can be identified in CRC by sequential genetic analysis of 
endothelial isolates from multiple biological replicates, and that this marker can be 
targeted through a vaccination-based approach to produce anti-angiogenic effects in 
a murine model of CRC, leading to a decrease in tumour growth.  
 
1.5.2 Validation of Potential Tumour Endothelial Markers in Colorectal Cancer 
A list of potential TEMs will undergo literature review, and those that prove to be 
novel within colorectal cancer will be taken forward to validation by real-time 
quantitative polymerase chain reaction (RTqPCR) and immunohistochemistry (IHC) 
on locally acquired clinical tissue samples. 
 
1.5.3 Functional Characterisation of TEMs in Endothelial Cell Behaviour 
Candidate genes of interest will be knocked down in human umbilical vein endothelial 
cells (HUVEC) using siRNA (small interfering RNA) duplexes. Manipulated cells will 
undergo assessment of cellular migration by a modified Boyden Chamber assay, 
vascular tube formation by Matrigel assay, chemotaxis and cellular communication 
by scratch wound assay and assessments of cell viability and proliferation will be 
made using the Acumen™ cell imager. 
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1.5.4 Investigation of Novel TEMs as Therapeutic Vaccines in Colorectal Cancer 
Newly identified TEMs, which are successfully validated, will be taken forward to a 
murine vaccine model. Self-antigens will be vaccinated against, using an adjuvant to 
facilitate breaking of immune tolerance. Vaccine effects on physiological 
angiogenesis will be investigated using the murine subcutaneous sponge assay, with 
tumour effects assessed using a subcutaneous tumour model. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 Equipment 
Centrifuges Source 
Biofuge Primo Heraeus, Newport Pagnell, UK 
Accuspin Micro Fisher Scientific, Loughborough, UK 
Mikro22R Hettich Zentrifugen, Tuttlingen, 
Germany 
Avanti J-20 XP Beckman Coulter, Brea, USA 
Harrier 18/80R MSE (UK) Ltd, London, UK 
 
Microscopes Source 
Leica DM6000 Leica, London, UK 
Leica DM1L Inverted Microscope Leica, London, UK 
USB 2.0 2M Xli Camera Xli, Carrollton, USA 
  
Spectrophotometer Source 
ND-1000 Spectrophotometer Nanodrop Technologies, Wilmington, 
USA 
  
Microtome Source 
5040 Microtome Bright Instruments, Cambridge, UK 
  
Biochemistry Source 
XCell SureLock™ Mini-Cell 
Electrophoresis Apparatus 
Invitrogen, Paisley, UK 
XCell II™ Blot Module Wet Transfer 
Apparatus 
Invitrogen, Paisley, UK 
Electrophoresis Power Supply EPS 
301 
Amersham Biosciences, Sweden 
Polyvinylidene Difluoride Membranes Immobilon-P, Billerica, USA 
Block Heater SBH 200D Stuart, Stone, UK 
Accublock™ Digital Dry Bath  Labnet International Inc., 
Woodbridge, USA 
Gyro-rocker SSL3 Stuart, Stone, UK 
Rotator SB3 Stuart, Stone, UK 
Heating Magnetic Stirrer FB15001 Fisher Scientific, Loughborough, UK 
EK-300i Measuring Scale A&D, Seoul, South Korea 
Roto-shake Genie Scientific Industries, New York, USA 
Compact x4 X-Ray Film Developer Xograph Imaging System, Tetbury, 
UK 
3510 pH Meter Jenway, Stone, UK 
HiTrap Protein A Column GE Healthcare Life Sciences, Little 
Chalfont, UK 
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Molecular Biology Source 
Orbital Incubator Gallenkamp, The Netherlands 
Stuart SI500 Shaking Incubator Stuart, Stone, UK 
GeneGenius Gel Imaging System Syngene, Cambridge, UK 
DNA Gel Tank Jencons (Scientific) Ltd, East 
Grinstead, UK 
Thermal Water Bath Fisher Scientific, Loughborough, UK 
DYAD DNA Engine Multi-Bay 
Thermal Cycler 
Life sciences, Little Chalfont, UK 
Rotor-Gene RG-3000 Corbett Life Sciences, Qiagen, 
Crawley, UK 
Vibracell Ultrasonic Processor Sonics & Materials, Newtown, CT, 
USA 
  
Cell Biology  
Sterile Cell Culture Hood, Advanced 
BioSafety Cabinet Class 2 
Microflow, Andover, UK 
Incubator, 37oC, 5% CO2, 95% 
Filtered Air 
Heraeus, Newport Pagnell, UK 
Water Bath Fisher Scientific, Loughborough, UK 
Haemocytometer Marienfeld, Lauda-Königshofen, 
Germany 
  
Facilities  
Biomedical Services Unit Birmingham, UK 
DNA Sequencing Service Technology Hub, Birmingham, UK 
Mass Spectroscopy Unit Technology Hub, Birmingham, UK 
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2.1.2 Consumables, Chemicals and Reagents 
Biochemistry Source 
Protein A Sepharose Beads Sigma, Gillingham, UK 
Glutathione Sepharose Beads GE Healthcare, Little Chalfont, UK 
Histoclear National Diagnostics 
Ultrapure ProtoGel Geneflow, Lichfield, UK 
Tween 20 Sigma, Gillingham, UK 
Ponceau S Sigma, Gillingham, UK 
TEMED Sigma, Gillingham, UK 
  
Molecular Biology Source 
ProbeLibrary Realtime PCR Assay 
System 
Exiqon, Woburn, USA 
Agarose Sigma, Gillingham, UK 
SYBR-safe DNA Gel Stain Invitrogen, Paisley, UK 
LB Broth Sigma, Gillingham, UK 
LB Agar Sigma, Gillingham, UK 
SOC Media Bioline, London, UK 
10mM dNTP Fermentas, Cambridge, UK 
EXPRESS qPCR Supermix Invitrogen, Paisley, UK 
6x DNA Loading Dye New England Biolabs, Herts, UK 
Fusion DNA Polymerase New England Biolabs, Herts, UK 
Taq DNA Polymerase Bioline, London, UK 
EcoR1 New England Biolabs, Herts, UK 
BamH1 New England Biolabs, Herts, UK 
EcoR1 Buffer New England Biolabs, Herts, UK 
Antarctic Phosphatase New England Biolabs, Herts, UK 
T4 Ligase Thermo Scientific, California, USA 
α-Select Competent E.coli Gold 
Efficiency 
Bioline, London, UK 
α-Select Competent E.coli Bronze 
Efficiency 
Bioline, London, UK 
BL 21 E.coli Bioline, London, UK 
  
Cell Biology Source 
RNAiMAX Lipofectamine Life Technologies, California, USA 
Actinomycin Life Technologies, California, USA 
Collagenase Type 1A Sigma, Gillingham, UK 
Collagenase Type 5 Sigma, Gillingham, UK 
Polyethylenimine (PEI) Sigma, Gillingham, UK 
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2.1.3 Oligonucleotides 
Primers for RTqPCR / DNA Sequencing 
Oligonucleotide Organism Sequence 
KCNJ8 Human F: 5’-CGCTACCCGGAGTCTGAG-3’ 
R: 5’-CAGCTTAGCCACCTCCCTCT-3’ 
Probe 34 
P2RY6 Human F: 5’-TGCTCCACGAGTGGGAAT-3’ 
R: 5’-GGTGGGTTTCCTATGTTCAGG-3’ 
Probe 67 
GRIN2D Human F: 5’-GGCTCAGTGACCGCAAGT-3’ 
R: 5’-GCACGGTCCCAAACTTCA-3’ 
Probe 57 
GRIN2D Mouse F: 5’-CCATTCTCGACTTCCTGTCG-3’ 
R: 5’-GCTGTTGCTCTGTGGAGGA-3’ 
Probe 4 
GRIN2D 
Reverse Cloning  
Human 5’-CTGATCGAATTCGCGCCCGGGCTG 
CGCACCGCCGCCGCCGCCACGGC-3’ 
LOC541471 Human F: 5’-CAGATCTTCACAGCACAGTTCC-3’ 
R: 5’-TGCTGATCCACTTTGCTTGT-3’ 
Probe 39 
LILRB4 Human F: 5’-ACCTTCACGGCTCTGCTCT-3’ 
R: 5’-CCCCCAGCTGATCACAGA-3’ 
Probe 57 
VASN Human F: 5’-CGCCAGGAAAGACTGAGG-3’ 
R: 5’-ACCCTGGAGCACATCTTCTG-3’ 
Probe 70 
OR51E1 Human F: 5’-CAGCCTGCCAGACCTCTT-3’ 
R: 5’-CAGCACCAGGCAGGTAGAG-3’ 
Probe 69 
GJA4 Human F: 5’-CCTCAAACCCTCTCCTCACA-3’ 
R: 5’-GCTCTGTCTGTGCGATCAAG-3’ 
Probe 3 
RGS16 Human F: 5’-GATCCGATCAGCTACCAAGC-3’ 
R: 5’-GTGGGTCTCATGGTCAATGTT-3’ 
Probe 37 
ADAP2 Human F: 5’-ACACCAGGAACCTGTTTGTGT-3’ 
R: 5’-GGAGGGCATTGAACCAGTC-3’ 
Probe 12 
PECAM Human F: 5’-GCAACACAGTCCAGATAGTCGT-3’ 
R: 5’-GACCTCAAACTGGGCATCAT-3’ 
Probe 14 
PECAM Mouse F: 5’-CGGTGTTCAGCGAGATCC-3’ 
R: 5’-ACTCGACAGGATGGAAATCAC-3’ 
Probe 45 
β -Actin Human F: 5’-CCAACCGCGAGAAGATGA-3’ 
R: 5’-CCAGAGGCGTACAGGGATAG-3’ 
Probe 64 
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β -Actin Mouse F: 5’- GGAGGGGGTTGAGGTGA-3’ 
R: 5’-GTGTGCACTTTTATTGGTCTCAA-
3’ 
Probe 71 
Flotillin Human F: 5’-GATCCTCAGCTTCACCATCAA-3’ 
R: 5’-TCAGCATCTCTCTGCACCAC-3’ 
Probe 61 
NOX4  Mouse F: 5’-
AGTATCAGACAAATGTAGACACTCACC-
3’ 
R: 5’-CTGGGATGATGTCTGGTTAAGA-3’ 
Probe 71 
STRA6 Mouse F: 5’-CTCAGCAAGGCCTCTCTCTTTC-3’ 
R: 5’-TGGGATGGGAGATATTCAGG-3’ 
Probe 9 
CMV Promoter Vector F: 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
pGEX 
Sequencing 
Primers 
Vector F: 5'-GGG-
CTGGCAAGCCACGTTTGGTG-3' 
R: 5'-CCG-
GGAGCTGCATGTGTCAGAGG-3 
 
2.1.4 Antibodies 
Specificity Characteristics Application/ 
Dilution 
Source Catalogue 
Number 
Anti-GST  Goat, anti-GST Western Blot 
1 in 2000; 
ELISA 1 in 
500 
GE Healthcare, 
Little Chalfont, 
UK 
27-4577-62 
Anti-Sheep 
Ig-HRP 
Rabbit, anti-
sheep, HRP 
conjugated 
Western Blot 
1 in 5000 
R&D Systems, 
Abingdon, UK 
HAF016 
Anti-Goat Ig-
HRP 
Rabbit, anti-
goat, HRP 
conjugated 
ELISA 1 in 
5000 
Dako, Ely, UK P0160 
Anti-Mouse 
Ig-HRP 
Rabbit, anti-
mouse IgG, 
HRP 
conjugated 
ELISA 1 in 
5000 
 
Dako, Ely, UK Z 0420  
 
Anti-Rabbit 
Ig-HRP 
Donkey, anti-
rabbit Ig, HRP 
conjugated 
Western Blot 
1 in 5000 
ELISA 1 in 
5000 
R&D Systems, 
Abingdon, UK 
HAF008 
Anti-Mouse 
IgG1 
Goat, anti-
mouse 
ELISA  
1 in 500 
Sigma, 
Gillingham, UK 
M5532 
Anti-Mouse 
IgG2a 
Goat, anti-
mouse 
ELISA  
1 in 500 
 
Sigma, 
Gillingham, UK 
M5657 
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Anti-Mouse 
IgG2b 
Goat, anti-
mouse 
ELISA  
1 in 500 
Sigma, 
Gillingham, UK 
M5782 
Anti-Mouse 
IgG3 
Goat, anti-
mouse 
ELISA  
1 in 500 
Sigma, 
Gillingham, UK 
M5907 
Anti-Mouse 
IgA 
Goat, anti-
mouse 
ELISA  
1 in 500 
Sigma, 
Gillingham, UK 
M6032 
Anti-Mouse 
IgM 
Goat, anti-
mouse 
ELISA  
1 in 500 
Sigma, 
Gillingham, UK 
M6157 
Anti-Human 
Clec-14a 
Sheep Anti-
human 
Western Blot 
1 in 1000 
R&D Systems, 
Abingdon, UK 
AF4968 
Anti-Fc-HRP  Goat Anti-
human, HRP 
conjugated 
Western Blot 
1 in 1000  
Abcam, 
Cambridge, UK 
ab97265 
Anti-
GRIN2D-N-
Terminus 
Rabbit Anti-
Human, custom 
polyclonal 
serum 
Western Blot 
1 in 500 
IHC undiluted 
Eurogentec, 
Seraing, 
Belgium 
 
ZGB14072 
- 0685 
Anti-
GRIN2D-N-
Terminus 
Rabbit Anti-
Human, 
polyclonal 
serum 
Western Blot 
1 in 500 
IHC undiluted 
Eurogentec, 
Seraing, 
Belgium 
ZGB14072 
- 0686 
ImmPRESS 
HRP 
Universal 
Secondary 
Antibody 
Donkey Anti-
mouse Ig & 
Donkey Anti-
rabbit Ig, 
HRP 
Conjugated 
IHC As 
supplied  
Vector 
Laboratories, 
Peterborough, 
UK 
MP-7500  
 
2.1.5 siRNA Duplexes 
Specificity Source Catalogue Number 
Scrambled 
Control 
Origene, Rockville, MD, USA SR30004 
Human 
GRIN2D 
Origene, Rockville, MD, USA SR301958A 
Human 
GRIN2D 
Origene, Rockville, MD, USA SR301958C 
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2.1.6 DNA Vectors and Plasmids 
 
Vector Characteristics Source 
pcDNA3.1 Mammalian Expression 
Vector. Human Fc Tag 
at C-Terminus 
Invitrogen, Paisley, UK 
pGEX-2T Bacterial Expression 
Vector. GST Tag at N-
Terminus 
GE Healthcare, Life 
Sciences, Little 
Chalfont, UK 
MSCV-Luc Retroviral Mammalian 
expression Vector. 
Luciferase insertion 
sequence. 
Clontech, California, 
USA 
 
2.1.7 Cell Lines 
 
Cell Line Source 
Human Umbilical Vein Endothelial 
Cells (HUVEC) 
Bicknell Lab, Birmingham University, 
UK 
SHSY5Y Nagy Lab, Birmingham University, UK 
HEK293-T Bicknell Lab, Birmingham University, 
UK 
CT26 Life Technologies, California, USA 
Phoenix-ampho Gary Nolan, Stanford, USA 
 
 
2.1.8 Cell Culture Media 
 
Media Source 
Foetal Calf Serum CRUK Central Services, London, UK 
Penicillin 10 000 units/ml + 
Streptomycin 10 000 µg/ml 
Gibco, Life Sciences, Gillingham, UK 
L-Glutamine Gibco, Life Sciences, Gillingham, UK 
OptiMEM Serum Low Media Invitrogen, Paisley, UK 
Medium 199 Sigma, Gillingham, UK 
Bovine Brain Extract Bicknell Laboratory, UK 
Heparin Sigma, Gillingham, UK 
Trypsin 0.5% Gibco, Life Sciences, Gillingham, UK 
DMEM Sigma, Gillingham, UK 
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2.1.9 Biological Materials and Solutions 
 
Material Company 
Balb/c Mice Charles River, Margate, UK 
Umbilical Cords NHS, Birmingham, UK 
Colorectal Cancer NHS, Birmingham, UK 
Normal Colon NHS, Birmingham, UK 
Matrigel BD Biosciences, Oxford, UK 
D-Luciferin PerkinElmer, Seer Green, UK 
Freund’s Complete Adjuvant Sigma, Gillingham, UK 
Freund’s Incomplete Adjuvant Sigma, Gillingham, UK 
 
 
2.1.10 Buffers and Solutions 
 
Buffer Recipe 
4x SDS Loading Buffer 2ml 1M Tris HCl(pH6.8), 0.8g SDS, 
0.04g Bromophenol Blue, 4ml 100% 
Glycerol, 4ml 1M DTT  
RIPA Buffer 300µl 5M NaCl, 1ml 10% NP40, 
500µl 10% DOC,  100µl 10% SDS, 
500µl 1M Tris HCl (pH 7.5), 7.6ml 
dH2O  
4x Resolving Buffer (250ml) 1g SDS, 42.25g Tris HCl pH8.8 
4x Stacking Buffer (250ml) 1g SDS, 15.125g Tris HCl pH6.8 
10x Western Blot Running Buffer (1L) 50ml 20% SDS, 30.2g Tris, 144g 
Glycine 
10x Western Blot Transfer Buffer (1L) 2.5ml 20%SDS, 2g Tris, 75g Glycine. 
Phosphate Buffered Saline – Tween 
20 (PBS-T) 
1L PBS, 500µl Tween-20 
Blocking Buffer 10% Skimmed Milk in PBS-T 
 
TAE Buffer 40mM Tris Base, 18mM Glacial 
Acetic Acid, 1mM EDTA 
E.coli Lysis Buffer 50mM Tris pH7.5, 100mM NaCl, 2mM 
EGTA, 2mM EDTA, 1mM DTT, 
0.5mM PMSF 
 
GST Wash Buffer 50mM Tris pH8.5, 100mM NaCl, 1mM 
DTT, 0.5mM PMSF 
GST Elution Buffer 30mM Reduced Glutathione, 50mM 
Tris pH8.5, 100mM NaCl, 1mM DTT, 
0.5mM PMSF, Protease inhibitors. 
GST-GRIN2D Storage Buffer 50mM MES pH 5.5, 150mM NaCl 
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2.2 METHODS 
2.2.1 Molecular Biology  
2.2.1.1 DNA/RNA Handling and Quantification 
All work with DNA or RNA was carried out using sterile pipette tips and nuclease-free 
(NF) water. DNA Samples were stored at -20oC and RNA samples at -80oC. DNA 
and RNA quantification was performed using the NanoDrop spectrophotometer 
(Thermoscientific, Wilmington, DE, USA), with the OD 260/280 ratio used as a 
measure of sample purity. 
 
2.2.1.2 RNA Extraction 
Total RNA was isolated from primary cells or cell lines using the RNeasy Mini-Kit  
(Qiagen, Crawley, UK) as per the kit protocol. To summarise: The cells were 
suspended in 700 µl Qiazol Lysis buffer, and then 140 µl chloroform was added. This 
mix was then centrifuged at 14,000g at 4oC for 15 mins, and the upper aqueous 
phase separated off. This phase was combined with 100% ethanol, and added to a 
centrifuge column. The column is then washed with Buffer RWT (Qiagen, Crawley, 
UK), and treated with RNase-free DNase. The column is further washed, and finally 
the RNA sample was eluted in RNase-free Water. 
 
2.2.1.3 Generation of Complementary DNA (cDNA) 
Following RNA isolation, cDNA was generated using the High-Capacity cDNA 
Reverse Transcription Kit (Life Technologies, California, USA), without RNase 
Inhibitor.  
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Reaction components: 
Component Volume per reaction (µl) 
10x RT Buffer 2.0 
25x dNTP Mix (100 mM) 0.8 
10x RT Random Primers 2.0 
Multiscribe™ Reverse Transcriptase 1.0 
Nuclease-Free H2O 4.2 
Total Volume Per Reaction 10.0 
  
The reaction master mix was then combined with an equal quantity (20 ng-2 µg) of 
RNA made up to 10 µl with H2O. Total reaction volume  = 20 µl 
Thermal Cycler Conditions: 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25oC 37oC 85oC 4oC 
Time 10 min 120 min 5 min ∞ 
 
2.2.1.4 Real-Time Quantitative Polymerase Chain Reaction (RTqPCR) 
All RTqPCR Reactions were performed using the Rotor-Gene RG3000 Thermal 
Cycler, and the ProbeLibrary PCR Assay System. Beta-Actin was used as the 
housekeeping gene to which the expression of each potential endothelial target was 
normalised unless otherwise stated.  Primer and Probe sets were designed using 
ProbeFinder Software (Roche Applied Science, Indianapolis, USA). Reaction mix 
was prepared in triplicate, and 10 µl of cDNA used for each reaction. Serial dilutions 
of 1:10, 1:100 and 1:1000 of cDNA were used to ensure internal experimental 
validity. 
 
Primer mix: 
Component Volume (µl) 
Forward Primer 10 
Reverse Primer 10 
Nuclease Free H2O 180 
 
!39!
Reaction Mix per reaction: 
Component Volume (µl) 
Primer Mix 2 
Probe 0.25 
Nuclease Free H2O 0.25 
Express qPCR Supermix  
(Life Technologies, Paisley, UK) 
12.5 
 
2.2.1.5 Agarose Gel Electrophoresis 
1% or 2% agarose gel was prepared in TAE Buffer with the addition of 1:10 000 
SYBR safe DNA gel stain (Invitrogen, Paisley, UK). 6x loading dye was added to the 
DNA, and the samples loaded. The samples were run at 100V for 30-45 mins. An 
ultraviolet (UV) image was acquired of the gel using the BIO Imaging System 
machine. Annotations were performed using Genesnap Software (Gene Genius, 
Cambridge, UK). 
 
2.2.1.6 Agarose Gel Extraction 
All procedures were performed using the GeneJET Gel Extraction Kit 
(Thermoscientific, Wilmington, DE, USA). Desired bands were visualised using UV 
light, and excised using a scalpel.  A 1:1 ratio of binding buffer was added to the 
excised gel slice, and incubated with agitation at 60oC for 10 mins.  For DNA 
fragments ≤500bp, a 1:2 ratio of isopropanol was added to aid DNA isolation. The 
solution was then added to a centrifugation column, washed using wash buffer, and 
eluted in 50 µl elution buffer. Samples were then stored at -20oC. Concentration of 
extracted DNA was confirmed on agarose gel. 
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2.2.1.7 Restriction Enzyme Digestion 
Appropriate restriction enzymes were utilised in appropriate buffers with BSA at 0.1 
mg/ml. Digestion was performed in accordance with the manufacturer’s instructions. 
To summarise, 2 µg of DNA vector was combined with 1 µl of each enzyme (usually 
equivalent to 10 units) for 60 mins at 37oC.  
 
2.2.1.8 Vector Dephosphorylation 
When necessary, the digested vector ends were dephosphorylated using antarctic 
phosphatase. 1 µl (5 units) of antarctic phosphatase was added to the restriction 
digest product, alongside a 1/10 volume of 10x of antarctic phosphatase reaction 
buffer. This was incubated at 37oC for 15-30 mins, and then heat inactivated at 65oC 
for 5 mins. 
 
2.2.1.9 Ligation 
All DNA constructs were generated using T4 ligase. Appropriate ratios of vector and 
insert DNA were calculated using online software, and combined with 1 µl T4 ligase 
and an appropriate volume of 10x ligase buffer. The reaction mix was then incubated 
at 22oC overnight. 
 
2.2.1.10 Bacterial Transformation 
‘Gold efficiency α-select’ competent E.coli (Bioline Reagents, London, UK) were used 
for transforming ligation products, while ‘Bronze efficiency α-select’ competent cells 
were used for plasmid amplification. BL21 cells (Bioline Reagents, London, UK) were 
used for protein expression. 50 µl of cells were thawed on ice for 30 mins. 5-50 ng of 
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plasmid DNA was added to the cells, mixed by flicking, and incubated on ice for 30 
mins. The mixture was then heat shocked in a water bath at 42oC for 30-45 seconds. 
The mix was then placed on ice for a further 2 mins, after which 200 µl of SOC media 
was added, and the resultant mix incubated at 37oC on an agitator for 60 mins. 100 
µl was then plated onto LB Agar plates containing an appropriate antibiotic. 
 
2.2.1.11 Plasmid DNA extraction from bacteria 
All extractions were performed using the GeneJET Plasmid Miniprep Kit (Fermentas, 
Thermoscientific, Wilmington, DE, USA). Briefly, cultured cells were centrifuged and 
pelleted. The pellet was then resuspended in 250 µl resuspension buffer, containing 
RNase, 250 µl lysis solution and 350 µl of neutralisation solution, mixing between 
each addition by inversion. The resultant mix was then centrifuged and the 
supernatant transferred to a spin column. Here, the DNA is bound, washed, and then 
eluted using either elution buffer or NF Water. 
 
2.2.1.12 DNA Sequencing 
This was performed by the Functional Genomics and Proteomics Facility, School of 
Biosciences, University of Birmingham, UK. Briefly, 250 ng of DNA was combined 
with 1 µl of forward or reverse primer (final primer concentration 3.2pM), and the mix 
made up to 10µl using NF water. This was then combined with 10 µl BigDye® 
Reaction Mixture (Life Technologies, California, USA) for further processing. Data 
outputs were analysed using Sequencher software (Gene Codes Corporation, Ann 
Arbor, USA 
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2.2.1.13 Haematoxylin and Eosin Staining 
Slides were incubated twice in xylene for 5 mins, then twice for 2 mins in 100% 
ethanol, 2 mins in 70% ethanol, and then washed in distilled water. The slides were 
then incubated with Mayer’s haematoxylin for 10 mins, followed by washing in warm 
tap water for 3 mins, and then in eosin for a further 10 mins. The slides were then 
washed sequentially in tap water, 70% ethanol, 100% ethanol, then twice in xylene 
for 2 mins. The sections were then mounted in DPX. 
 
2.2.1.14 Immunohistochemical Staining 
Paraffin embedded sections were initially placed in xylene for 5 mins, then into 100% 
ethanol for 5 mins, then rehydrated by washing in water. Endogenous peroxidase 
block was performed using 0.3% hydrogen peroxide for 15 mins. The slides were 
then washed with water, and antigen retrieval was performed by incubating overnight 
in 1 mM EDTA pH 8.0 with 0.1% Tween in a beaker at 65oC, with stirring overnight. 
The following day, the beaker was cooled with running water until at room 
temperature. The slides were then washed with PBS for 5 mins, and then were 
treated with 100 µl of 2x casein block. The slides were then incubated with primary 
antibody at the desired concentration for 1 hour. Following this, the slides were 
washed with PBS-T for 5 mins, and then incubated for 30 mins with Vector 
ImmPRESS universal secondary antibody. Then the slides were washed with PBS-T 
for 5 mins, and then washed in PBS prior to visualisation by incubation with Vector 
ImmPACT DAB chromogen for 5 mins. The slides were then washed with water for 5 
mins prior to a 1 min counterstain using Meyer’s Haematoxylin. The slides were then 
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dehydrated using sequential 5 min washes with water, 100% ethanol, and xylene, 
and then mounted in DPX. 
 
2.2.2 Cell Biology  
All cell biology work was performed in a Class 2 isolation hood, utilising aseptic 
precautions. 
 
2.2.2.1 HUVEC Isolation and Culture 
HUVEC were isolated from fresh umbilical cords acquired from the Birmingham Bio 
Bank following patient consent in accordance with UK ethics Approval. Cords were 
washed with sterile PBS to remove any residual blood or debris.  1 mg/ml 
Collagenase A diluted in Medium-199 was then injected into the umbilical vein at an 
appropriate volume to the cord size, and incubated at 37oC for 20 mins to detach the 
endothelial cells.  The cord was then flushed with Medium-199 supplemented with 
10% FCS, 10% large vessel endothelial cell growth supplement, 4 mM L-glutamine  
(cM199) to isolate the HUVEC. They were then seeded onto plates coated with 0.1% 
Type 1 porcine gelatine, and cultured in cM199. The cells were then passaged one in 
three when they reached confluence. 
 
2.2.2.2 Adherent Cell Culture 
All cell culture was performed at 37oC in a 5% CO2 atmosphere. HEK 293T, CT26 
and SHSY5Y cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FCS, 4 mM L-Glutamine, 50 000 Units Penicillin and  
50 000 µg Streptomycin (cDMEM), with HUVEC cultured in cM199.  
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2.2.2.3 Trypsinisation of Adherent Cells 
Media was removed from the plate, and the cells washed with sterile PBS. For a 10 
cm Plate, 1 ml of 2x Trypsin/EDTA was applied, and incubated at 37oC for 10 mins. 
Cells were totally detached by pipetting of the trypsin over the plate surface. 10 ml of 
cDMEM was used to neutralise the trypsin and place the cells into suspension. The 
cells were then centrifuged for 5 mins at 1100 rpm, and the cell pellet subsequently 
resuspended in media at a suitable volume for cell counting, or for replating. 
 
2.2.2.4 Cell Counting 
10 µl of suspended cells were added to a haemocytometer (Marienfeld-Superior, 
Lauda-Königshofen, Germany). The cell number per ml was calculated using the 
following formula: (Count from 4x4 grid)x104 = cell number/ml 
 
2.2.2.5 Freezing and Thawing of Cells 
Cryopreservation of cells was achieved following release of adherent cells and 
centrifugation at 1100 rpm for 5 mins. Cells were resuspended in filtered FCS 
containing 10% DMSO at 4oC. 1 ml of suspended cells were aliquoted into cryovials, 
which were placed into a freezing container (Thermo Scientific, Langenselbold, 
Germany) at room temperature, then immediately transferred to the -80oC Freezer, 
ensuring a cooling of 1oC per minute. The following day, the cryovials were 
transferred to Liquid Nitrogen storage. 
Thawing of cells was conducted by transferring cryovials from liquid nitrogen storage 
to at circulating water bath at 37oC. The suspended cells were then transferred to a 
15 ml falcon tube, and diluted with 9ml of complete media.  These suspended cells 
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were then centrifuged at 1100 rpm for 5 mins, and this process completed twice to 
remove the DMSO. Finally cells were resuspended in complete media and replated. 
 
2.2.2.6 Isolation of Endothelial Cells from Human Colon 
Method adapted from ‘Validation and identification of tumour endothelial markers and 
their uses in cancer vaccine.’ Zhuang, Xiaodong (2013)  Ph.D. thesis, University of 
Birmingham: 
Fresh specimens of both colorectal cancer and patient matched normal colonic tissue 
were obtained from the Queen Elizabeth Hospital Birmingham with patient consent 
and ethical approval (South Birmingham Local Research Ethics Council: 2003/242). 
Normal colonic tissue was taken from the proximal margin of the resection specimen 
to ensure the greatest distance from the tumour, without affecting histopathological 
staging. Endothelial isolation was commenced within 1 hour of the specimen being 
removed from the patient.  
Tissues were mechanically disrupted with a scalpel, and then digested to a cell 
suspension in DMEM containing 2 mg/ml Collagenase Type V (Sigma, Gillingham, 
UK), 7.4 mg/ml of actinomycin (Sigma, Gillingham, UK), and 30 kU/ml of RNase-free 
DNase (Qiagen, Crawley, UK) for 90-120 mins at 37oC on an agitator.  50 µl of 
Streptavidin-coated Dynabeads® (Invitrogen, Paisley, UK) per sample were 
incubated with 25 µl of 20 mg/ml of biotinylated lectin from Ulex Europaeus for 30 
mins at 4oC.  
The cell suspension was then passed through a 70µm filter, the flow-through 
centrifuged at 1100 rpm for 5 mins, and the pellet resuspended in sterile PBS. This 
process was repeated a further two times. Dynabead-bound endothelial cells were 
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then isolated by passage alongside a magnet, and suspended in 700 µl Qiazol lysis 
buffer (Qiagen, Crawley, UK) for subsequent RNA extraction.  
 
2.2.2.7 Isolation of Endothelial Cells from Murine Tissue 
On the day before endothelial isolation, 50 µl of Dynabeads ((Invitrogen, Paisley, UK) 
per sample were washed and suspended in 2 ml of 0.1% BSA. 5 µl Anti-mouse 
PECAM-1 antibody was then added to the Dynabeads, and the tube mixed on a 
rotator overnight at 4oC. Following euthanasia by a Schedule 1 method, mice were 
submerged in 70% ethanol, and the organs dissected out, and stored in cDMEM. 
Each specimen was mechanically disrupted using a scalpel, and then suspended in 
25 ml Type 1 Collagenase (Sigma, Gillingham, UK) 2 mg/ml 1% BSA supplemented 
with 1 µl 1M CaCl2 and 1 µl MgCl2. The sample suspension was then agitated at 
37oC for 60 mins, and subsequently passed through a 70 µm cell strainer into a fresh 
50 ml tube.  The filtrate was subsequently centrifuged at 1300 rpm for 5 mins at 4oC, 
and the supernatant discarded. The pellet was then resuspended in 25 ml 0.1% BSA, 
and the centrifugation and aspiration repeated. The resulting pellet was resuspended 
in 1 ml 0.1% BSA, and the Dynabead-bound endothelial cells were then isolated by 
passage alongside a magnet, and suspended in Qiazol lysis buffer (Qiagen, Crawley, 
UK) for subsequent RNA extraction.  
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2.2.2.8 Generation of Luciferase-Transduced CT26 (CT26-Luc) Cell Line 
Initially, a lentiviral supernatant was generated by lipofectamine transfection:  
Phoenix-ampho cells (courtesy of Gary Nolan, Stanford, USA) were cultured in high 
glucose DMEM. 2x106 cells were then seeded to each 6 cm plate in high glucose 
DMEM. The following day, 10 µg of MSCV-Luc (88) plasmid DNA (Clontech, 
California, USA) in 500 µl Optimem medium was combined with 20 µl Lipofectamine 
2000 (Life Technologies, California, USA) in 500 µl Optimem to make a total of 1ml. 
This was incubated at room temperature for 20 mins.  The medium was removed 
from the plated cells, and they were washed with 3 ml Optimem. This was discarded, 
and a further 4 ml Optimem, and the 1 ml of transfection mix were added to the plate. 
This was then incubated overnight at 37oC, 5% CO2. The following day, the medium 
was changed to 4 ml cDMEM, and the plate was then incubated at 32oC, 5% CO2. 
Viral supernatant was then collected over the next five days, centrifuged at 1100 rpm 
for 10 mins to remove cellular debris and stored at -80oC.This was followed by 
transduction of CT26 Cells:  
1x105 CT26 Cells were plated per well of a 6-well plate in cDMEM. The following day, 
the medium was replaced with 2 ml DMEM with 4 µg/ml polybrene, and incubated for 
5 mins at room temperature. 2 ml viral supernatant supplemented with 4 µg/ml 
polybrene was then added to the plate and the plate centrifuged for 1 hr at room 
temperature at 300g. The medium was then replaced with 4 ml DMEM, and 
incubated again for two days. Following this, the cells were assayed for gene 
expression following puromycin selection using the In Vivo Imaging System 
(PerkinElmer, Waltham, MA, USA) (IVIS) to detect bioluminescence. Technique 
optimised by Joseph Wragg (Bicknell Laboratory). 
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2.2.2.9 Generation of Vector containing GRIN2D-Fc Fusion DNA 
The insert DNA for the extracellular domain of GRIN2D was generated by IDT 
Technologies, and delivered in the pIDTSmart-Amp Vector.  The insert was digested 
from the pIDTSmart vector using the EcoR1 and BamH1 restriction sites using a 
double digestion technique, and ligated in a single reaction into the pIgG (pcDNA3-
Fc) vector using the same sites and T4 ligase. Following ligation, heat-shock 
transformation of ‘gold efficiency α-select’ cells was performed, followed by overnight 
culture on ampicillin plates. Colonies were picked and grown up overnight, and then 
DNA extracted using the GeneJET Miniprep kit. These samples were sequence 
verified using GRIN2D Gene Expression Reverse primer and Forward primer to the 
CMV Promoter region of the PIgG plasmid. The derived construct was scaled up by 
maxi-prep and stored at -20oC. It is referred to as the pIgG-GRIN2DVector. 
 
2.2.2.10 Generation of Vector containing GRIN2D-GST Fusion DNA 
The insert DNA for the extracellular domain of GRIN2D was digested out of the 
GRIN2D-PIgG vector using the EcoR1 and BamH1 restriction sites using a double 
digestion, and ligated in a single reaction into the pGEX-2T vector (GE Healthcare, 
Life Sciences, Little Chalfont, UK) using the same sites and T4 ligase. Following 
ligation, heat-shock transformation of ‘gold efficiency α-select’ cells was performed, 
followed by overnight culture on ampicillin plates. Colonies were picked and grown 
up overnight, and then DNA extracted using the GeneJET Miniprep kit. These 
samples were sequence verified using the forward and reverse pGEX sequencing 
primers (GE Healthcare, Life Sciences, Little Chalfont, UK). The derived construct 
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was scaled up by maxi-prep and stored at -20oC. This vector was named the 
pGEX2T-GRIN2D Vector. 
 
2.2.2.11 Polyethylenimine (PEI) Transfection of HEK293T Cells 
For a 15 cm plate, on the day before transfection 6x106 HEK293T cells were plated 
out in 20 ml cDMEM. The following day, 18 µg of DNA was combined with 2 ml of 
Optimem serum-free media, and mixed by flicking of the tube. 72 µg of PEI was then 
added and briefly vortexed at low speed to mix, followed by a 10 min incubation at 
room temperature. The mixture was then gently added to the HEK293T cells and 
mixed by north/south east/west movements.    
 
2.2.2.12 – siRNA Knockdown of Novel TEMs in HUVEC 
1.75x105 HUVEC at passage 3 were plated into each well of a 6-well plate coated in 
0.1% gelatine. These cells were incubated overnight at 37oC. A mix of 2.5 µl of 20 
µM siRNA duplex and 167.5 µl Optimem (final duplex concentration of 50 nM), and a 
mix of 3 µl RNAiMAX lipofectamine and 27 µl Optimem were incubated at room 
temperature for 10 mins. 30 µl of lipofectamine mix was added to the duplex mix, 
flicked to combine, and incubated at RT for 10 mins. The seeded cells were then 
washed twice with PBS, and 800 µl of Optimem was added. Then 200 µl of 
lipofectamine/duplex mix was added to the cells, and incubated at 37oC for 4 hrs. At 
this stage, the media was aspirated off, and replaced with cM199 without antibiotics. 
The following day, the cells were harvested and assays performed. 
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2.2.2.13 – Scratch Wound Assay 
3x105 HUVEC were plated into each well of a 6-well plate and cultured in cDMEM at 
37oC. Once the cells were confluent, a P200 pipette tip was used to make three 
parallel scratches both vertically and horizontally, resulting in 9 intersections. The 
plate was then washed twice with PBS to remove any floating cells. Images were 
taken at 0 hrs, 6-8 hrs and 16-24 hrs to measure wound closure. 
 
2.2.2.14 – Matrigel Tube Forming Assay 
A 1 ml aliquot of Matrigel was retrieved from the -80oC freezer, and allowed to defrost 
overnight in the cold room at 4oC and on ice. The following day, the wells of a 12-well 
plate were moistened with PBS, which was then removed to leave a thin film within 
the well. 70 µl of Matrigel was added to each well, and then allowed to solidify at 
37oC for 30 mins. 1.4x105 cells were added to each well in 1 ml cM199. The assay 
was incubated for 16-24 hrs, and then images acquired to measure tube number, 
length and branching. 
 
2.2.2.15 – Transwell Filter Assay (Modified Boyden Chamber Assay) 
700 µl of 0.1% gelatine was added to each well of a 24-well plate, and then a cell 
permeable membrane was placed into the well, followed by a further 200 µl of 
gelatine. This was incubated at 37oC for 10 mins, then aspirated off. 700 µl of cM199 
was added to the bottom of the well, with 3x104 HUVEC in low-serum M199 (1% FCS 
& no brain extract) placed on top of the filter. The assay was then incubated for 16-24 
hrs. 
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Following incubation, the media was removed, and the wells washed with 700/200 µl 
of PBS. The PBS was then removed and replaced with equivalent volumes of fixing 
solution containing 2% Formaldehyde in PBS + 2 µg/ml bisbenzamide for 15 mins. 
The fixing solution was then removed and the wells and filters washed with PBS.  
To mount the filter, initially a drop of PBS was placed onto a slide, and then the filter 
was placed on top of this. A scalpel was used to excise the filter from its mounting, 
and the excess PBS wiped away. A drop of Shandon Immu-Mount(TM was added to 
the filter, and a coverslip applied. The slides were then stored in the dark at 4oC until 
ready to be imaged. To quantify this assay, the slide was visualised at 20x 
magnification, and counts made of those cells atop and below the filter by adjustment 
of the focus. These scores from 5-10 sites on the slide were averaged, and the 
figures used to quantify percentage transmigration. 
 
2.2.2.16 – Acumen 
On Day 2 following siRNA knockdown, media was removed and cells fixed using 100 
µl 100% ethanol at -20oC. The cells were then washed with PBS and incubated with 
RNase in PBS (0.2 mg/mL, DNase free) for 4 hrs at room temperature. 
Subsequently, nuclei were stained with propidium iodide (3 µM) for 15 mins at room 
temperature. The plate was scanned on an Acumen Explorer fluorescence 
microplate cytometer (TTP LabTech, Royston, Herts, UK), (Nagy Laboratory, 
Birmingham UK).  
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2.2.2.17 – Cytospin 
A suspension of 5x105 cells/ml was made. 200 µl of this cell suspension was then 
loaded into the cytospin cuvette, above blotting paper and a cytospin slide. The cells 
were then centrifuged at 800 rpm for 3 mins with a Cytospin 3 machine (Shandon, 
Loughborough, UK). The blotting paper and cuvette were carefully removed, and the 
slide air-dried. Cells were then fixed by immersion in 50% Ethanol / 50% Acetone for 
10 mins. Following this, they were stored at room temperature until further assays 
were performed. 
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2.2.3 Protein Analysis 
2.2.3.1 Protein Quantification 
Protein was quantified either by using the Protein A280 protocol on the NanoDrop 
machine, or by utilisation of the Pierce™ BCA™ Protein Assay Kit (Thermoscientific, 
Wilmington, DE, USA). This latter method was used when low protein concentrations 
were expected, or particularly accurate readings were necessary.  The nanodrop 
spectrophotometer was used for more approximate readings. 
 
2.2.3.2 Western Blotting 
Cell lysates were prepared using RIPA buffer. Protein samples were mixed with 4x 
SDS Loading buffer in an appropriate volume, and denatured by boiling for 3 mins. 
Samples were loaded onto an SDS-Polyacrylamide Gel for electrophoresis (SDS-
PAGE). Electrophoresis was performed in running buffer at 200V with time 
dependent on gel concentration and expected band size. The gel was then blotted 
onto a polyvinylidene fluoride (PVDF) membrane in transfer buffer at 30V for 120 
mins at 4oC. The membrane was blocked for 60 mins at RT with 10% milk in wash 
buffer (PBS with 0.05% Tween-20). Following blocking, the membrane was washed 
(4x 5 min) in wash buffer, then incubated with primary antibody in wash buffer with 
3% BSA for 60 mins at RT. Following further washes, horseradish peroxidase (HRP)-
conjugated secondary antibody with a 1 in 10 000 dilution in blocking buffer was 
applied for 60 mins at RT. 
Following antibody staining, the membrane was washed further and 500 µl of 
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enhanced chemiluminescent western blotting detection agent was added for 3 mins. 
A piece of photographic film was then exposed to the membrane for different lengths 
of time dependent on the luminescence of the HRP. 
 
2.2.3.3 Coomassie Brilliant Blue Staining 
Following SDS-PAGE, when non-specific protein identification was required, 
overnight staining in Coomassie brilliant blue at RT was utilised. The gel was then 
washed in dH20 to remove non-specific binding and visualised using a yellow filter 
and the BIO Imaging System Machine. 
 
2.2.3.4 Enzyme-Linked Immunosorbent Assays (ELISA) 
A Nunc Maxi-Sorp™ ELISA plate (eBioscience, Hatfield, UK) was coated with 100 µl 
of 2 µg/ml of GRIN2D-GST or Fc protein, and incubated overnight at 4oC. The plate 
was blocked using 200 µl 3% BSA in PBS-T for at least 2 hrs. The plate was then 
washed 5 times with 100 µl PBS-T, and then 5 µl of serum in 45 µl PBS was 
incubated overnight in each well at 4oC. The following day, the serum was removed, 
and the plate washed 5 times. For antibody isotyping, 100 µl of primary antibodies at 
1 in 500 were incubated for 90 mins. The plate was then washed 5 times. 
Peroxidase-conjugated anti-mouse IgG antibody (1 in 5000) was then applied as a 
secondary for 90 mins. The plate was incubated for 15 mins in detection solution (10 
mg o-phenylenediamine dihydrochloride (OPD) in sodium perborate/phosphate 
citrate buffer), and then quenched with 50 µl 3M HCl. Imaging was performed using a 
plate reader at 490 nm. 
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2.2.4 Protein Production 
2.2.4.1 Production and Purification of GRIN2D-Fc fusion protein 
Following PEI transfection of twenty 15 cm tissue culture plates, cells were grown in 
cDMEM until near confluence. Then the media was replaced with Optimem serum-
free media, and the media collected and refreshed every two to three days for up to 
21 days, giving a total conditioned media volume of 3-5 litres. 1 mM EDTA and a few 
phenylmethylsulfonyl fluoride (PMSF) crystals were added to the collected media to 
inhibit any contaminant proteases present.  
A HiTrap Protein-A column (GE Healthcare, Life Sciences, Little Chalfont, UK) was 
flushed with filtered 20% ethanol, and pH equilibrated using monosodium phosphate 
(NaH2PO4) at pH 7.0. Conditioned media was run through the column at 1 ml/min at 
4oC followed by a further 30 ml wash with NaH2PO4 to remove non-specific protein. 
The protein was eluted using sodium citrate 100 mM pH 3.0 in 500 µl fractions and 
immediately pH neutralised using 110 µl 1M Tris-HCl pH 9.5. Fractions were 
analysed for the presence of protein, and those with a significant eluate pooled. Final 
protein concentration was measured by BCA Protein assay, after which the protein 
was sterile filtered and stored at 4oC. 
 
2.2.4.3 Production and Purification of GRIN2d-GST fusion protein 
50 µl BL21 E.coli were transformed as previously described using the pGEX-2T-
GRIN2D Vector.  Overnight cultures of transformant colonies underwent DNA 
extraction using the mini-prep protocol, and were then sequence verified. Stock 
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cultures were made by dilution of 10 ml overnight culture in 10 ml of LB Broth with 
10% glycerol, aliquoted to 1 ml, and stored at -80oC.   
For large-scale protein expression, 1 ml of stock culture was diluted in LB Broth with 
100 µg/ml ampicillin, and incubated overnight while shaking at 37oC. The following 
day, 25 ml of this overnight culture was inoculated into 500 ml LB broth with 
ampicillin, and again incubated at 37oC while agitating for 120 mins to achieve an 
OD600 of 0.6, indicating the bacteria were in the log growth phase. At this stage, 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 1 mM concentration was added to 
induce protein expression. The cells were then incubated for 4 hrs at 37oC. Following 
incubation, the cells were centrifuged at 5 500 rpm at 4oC for 15 mins. Bacterial 
pellets were then washed in E.coli lysis buffer and stored at -80oC. 
Pellets were thawed on ice, and resuspended in 2 ml E.coli Lysis Buffer per 100 ml of 
original bacterial culture. The sample was then sonicated at 10W for 4 mins on ice 
(20s on, then 10s off to prevent warming of sample. 100x Triton was the added to the 
sample to a final concentration of 1%, and the sample vortexed, then incubated on 
ice for 30 mins. The sample was then divided into 1ml aliquots and centrifuged at      
14 000 rpm at 4oC for 15 mins. The supernatant was then pooled. 
Glutathione sepharose beads (Sigma, Gillingham, UK) were washed three times in 
E.coli lysis buffer, and then combined with the pooled bacterial lysate. 1 ml of beads 
was used for 2 litres of bacterial culture. This was incubated on a wheel at 20 rpm at 
RT for 2 hrs. Following incubation, the beads were washed twice with 20 ml wash 
buffer. The GST-fusion protein was then either eluted off the beads or on-bead 
thrombin digestion was performed.  For elution, the beads were incubated with 1 ml 
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of elution buffer, containing 30 mM reduced glutathione, for 30 mins at room 
temperature. A second elution was performed to ensure complete protein retrieval.  
 
2.2.4.4 Buffer exchange 
Following elution of GRIN2D-GST, buffer exchange was performed using at PD10 
Desalting Column (GE Healthcare, Life Sciences, Little Chalfont, UK). Briefly, the 
column was equilibrated by washing with 25 ml of the collection buffer of choice, and 
the flow-through discarded. 2.5 ml of sample was added, and the flow-through 
discarded. Then a further 3.5 ml of collection buffer was added, and the eluate 
collected. 
 
2.2.4.6 Size Exclusion Chromatography (SEC) 
Protein samples that required purification underwent SEC using a HiLoad 16/600 
Superdex 200 PG column (GE Healthcare, Little Chalfont, UK), with an AKTA Fast 
Protein Liquid Chromatography (FPLC) machine (Bio-Rad Healthcare, GE, Little 
Chalfont UK). Briefly, the column was washed with 2 column volumes of an 
appropriate FPLC Buffer. The sample was then loaded at room temperature, and 
passed through the column at 3 ml/min. 5 ml fractions were collected, and the 
fractions analysed by SDS-PAGE prior to pooling and concentrating with a VivaSpin 
Column (eBioscience, Hatfield, UK) to a useable concentration. 
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2.2.5 Animal Models 
2.2.5.1 Home Office Licence Training 
In order to undertake scientific procedures on animals, Home Office training for a 
personal license under the Animal (Scientific Procedures) Act 1986 was undertaken 
and successfully completed.  The personal license number 70/25131 was gained, 
and subsequently transferred to the electronic license system, with the designation 
I350D34BB. 
All work was carried out under the Project License 40/3339 held by Roy Bicknell. 
 
2.2.5.2 Murine Subcutaneous Colorectal Cancer Model 
Balb/c mice were anaesthetised using inhaled Isofluorane, and following confirmation 
of depth of anaesthesia with a toe pinch, the left flank was shaved.  Anaesthesia was 
maintained using a facemask. 1x105 Luciferase-transduced CT26 (CT26-Luc) 
colorectal cancer cells were injected into the left flank of each mouse. A one-week 
tumour establishment period was allowed, following which regular tumour calliper 
measurement was performed. This was combined with intraperitoneal injection of 
200 µl of 15 mg/ml D-Luciferin in PBS, and tumour growth measurement using the 
intravital imaging system (IVIS). 
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2.2.5.3 Murine Subcutaneous Sponge Model 
Buprenorphine was administered 1 hour prior to surgery. NSAIDs were avoided due 
to potential confounding effects on angiogenesis. Balb/c mice were anaesthetised 
using inhaled Isofluorane, and following confirmation of depth of anaesthesia with a 
toe pinch, both flanks were shaved.  The skin was cleansed with ethanol. A small 
incision was made in the flank and a subcutaneous pocket created by blunt 
dissection. A 0.5 x 1.0 cm cylindrical sponge was inserted into the sub-cutaneous 
pocket and the skin closed using 6/0 absorbable subcuticular sutures. This was then 
repeated for the other flank. Over the next 14 days, 100 µl of 20 ng/ml bFGF was 
injected into the sponge a total of 7 times, with a minimum of 12 hrs between 
injections. Animals were culled by a schedule 1 method, and the sponges fixed in 4% 
formalin prior to histological analysis. 
 
2.2.5.4 Murine Vaccination Model 
Balb/c mice were anaesthetised using inhaled Isofluorane, and following confirmation 
of depth of anaesthesia with a toe pinch, 100µl Freund’s Complete Adjuvant was 
injected subcutaneously with 50µg of either treatment or control protein. After 14 
days, 100µl Freund’s Incomplete Adjuvant was injected subcutaneously with 50µg of 
either treatment or control protein to boost the host antibody response. Tail vein 
bleeds were performed at days 0, 14 and 28, with antibody response quantified by 
ELISA. 
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2.2.5.6 Colonic Tissue Acquisition and Ethical Considerations 
The acquisition of colorectal cancer and normal colon tissue was approved by the 
South Birmingham Local Research Ethics Committee, with the approval number 
2003/242. 
Informed consent for acquisition of tissue was taken from patients by one of three 
researchers (Henry Ferguson, Steven Ward, Elizabeth Hepburn), using both the 
University Hospitals Birmingham NHS Trust’s formal consent form, and the approved 
University of Birmingham consent form. 
Following surgical resection, the named researchers entered theatre with permission, 
and retrieved the resection specimen. This was then transported to the Department 
of Histopathology, where it was sectioned for histological diagnosis by a Consultant 
histopathologist. Only remnants of the resection specimen not necessary for patient 
care or diagnosis were then taken for further processing. 
The patient information that was collected for the purpose of this research was 
limited to name, gender, date of birth and hospital number, alongside a diagnosis of a 
colorectal malignancy. These details were stored on the patient consent form only, in 
a secured, locked filing cabinet in a non-public secured office within the Institute for 
Biomedical Research at the University of Birmingham.  All samples were 
subsequently anonymised, and no patient identifiable data was released or used 
within any analysis, nor will it be included in any publications or presentations of this 
work in an academic or public forum. 
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2.2.6 Bioinformatic Websites 
 
Universal ProbeLibrary Assay Design Centre: 
https://www.roche-applied-science.com 
 
NCBI: 
http://ncbi.nlm.nih.gov/ 
 
TMHMM Server v2.0 (Transmembrane Region Prediction): 
http://www.cbs.dtu.dk/services/TMHMM 
 
Clustal Omega Genome Sequence Alignment Tool: 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
 
Protease cutting site prediction: 
web.expasy.org/peptide_cutter 
 
Protein Secondary Structure Prediction:  
http://bioinf.cs.ucl.ac.uk/psipred and http://swissmodel.expasy.org/ 
 
Vector Insert Ratio Calculator 
http://www.insilico.uni-duesseldorf.de/Lig_Input.html 
 
Statistical Testing: 
http://vassarstats.net/ 
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2.2.7 Statistical Methods 
A minimum 95% confidence interval was used in all statistical tests. All error bars 
depict standard error of the mean (SEM). Non-parametric data distributions were 
assumed in all analyses. Mann-Whitney U Tests were used to compare two groups, 
with ANOVA tests used to compare multiple groups. 
p-value Depiction 
<0.001 *** 
To 0.01 ** 
0.01 to 0.05 * 
>0.05 Non-Significant (ns) 
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CHAPTER THREE 
 
IDENTIFICATION AND VALIDATION OF NOVEL 
TUMOUR ENDOTHELIAL MARKERS IN 
COLORECTAL CANCER 
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3.1 IDENTIFICATION OF NOVEL TEMs IN COLORECTAL CANCER 
 
This chapter describes the process of the identification of GRIN2D as a putative 
endothelial target in CRC from an initial list of candidates provided by microarray 
analysis of gene expression, through RTqPCR analysis of multiple biological 
replicates, and finally confirmation of endothelial expression through 
immunohistochemistry. Later, the in vitro effects of knockdown of the genetic 
expression of GRIN2D in HUVEC are described, focussing on its effects on 
angiogenesis. 
 
3.1.1 – Isolation of Endothelial Cells from Fresh Colorectal Resection Specimens 
In order to maintain the RNA expression profile of the specimens, fresh colorectal 
resection specimens were obtained in person from the operating theatres at the 
Queen Elizabeth Hospital in Birmingham, and transferred to the histopathology 
department of the same hospital. Here, an available consultant histopathologist cut 
small sections of the specimen from both the malignant lesion, and from non-
diseased proximal colon, away from areas needed for clinical diagnosis or 
prognostication. The sections were then processed within 2 hrs of resection, as 
described in Section 2.2.2.6. RNA was extracted, and assessed for integrity using the 
Agilent Bioanalyzer 2100 (by Steve Kissane, Birmingham University, UK). Those 
paired samples with an RNA integrity number (RIN) of greater than 7.0 were taken 
forward. The RIN is a validated method for estimation of RNA integrity, which has 
been shown to reliably predict, quantify the quality of extracted RNA(89). Essentially, 
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it measures the number of RNA fragments present, and their size by means for laser 
induced fluorescence, and is an integral function of the Agilent Bioanalyzer 2100.  
Endothelial enrichment was confirmed by RTqPCR quantification of the expression of 
platelet endothelial cell adhesion molecule (PECAM-1 or CD31) when normalised to 
the consistently expressed, ‘housekeeper’ molecule beta-actin. PECAM is a highly 
endothelial-specific protein(90), and can hence be used to quantify enrichment of 
endothelial cells within a sample. Relative expression was calculated using the 2-ΔΔCT 
method, a validated mode of analysis for this purpose(91). PCR analyses were 
performed in triplicate for each sample to eliminate internal experimental error, and 
repeated using multiple biological replicates. 
 
3.1.2 – Microarray Identification of Gene Candidates (Performed by Joseph Wragg) 
Differential gene expression profiles between four colorectal cancer specimens, and 
patient-matched normal colon was performed using an Agilent™ Microarray. Briefly, 
the extracted RNA from fresh colorectal samples was confirmed as having an RIN>7, 
and then utilised to generate complimentary DNA. This cDNA was used to generate 
complementary RNA, which was then fluorescently labelled with the cyanine dye 
Cy3. This cRNA was hybridised onto the microarray chip (Steve Kissane, 
Birmingham University, UK), and then imaged. 
The resultant data gave absolute gene expression values across the human genome 
in triplicate (3x20 000 genes per sample). Those genes that were predicted to code 
for transmembrane proteins, and were greater than five times upregulated 
consistently across the multiple biological replicates used for the microarray were 
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taken forward as potentially targetable endothelial proteins. This gave 28 potential 
candidates: !
EGFL6 THBS2 HSD11B1 TRIB3 
IL6 NOTCH3 PLXDC1 GJA4 
GRIN2D PDGFRB FZD10 VASN 
WNT2 LOC541471 LILRB4 IL13RA2 
FCGR3A P2RY6 LINGO1 PGF 
LZTS1 KCNJ8 SLAMF8 RGS16 
MARCO OR51E1 GJA4 ADAP2 
 
Table 2 – Transmembrane Gene Candidates from Microarray Analysis of CRC 
versus Patient-Matched Normal Colon. 
 
3.1.3 – Narrowing the Shortlist 
From this long-list, extensive literature and bioinformatic review was undertaken to 
reduce the shortlist. Those genes that were previously published as tumour 
endothelial markers, or were under study or patent with another institution were 
excluded from further work. Preference was given to those genes encoding known 
endothelial proteins, or those with published links to the vasculature or 
carcinogenesis. All gene-coding details were taken from GeneCards 
(www.genecards.org), as was all data on protein function and associated pathology 
unless otherwise referenced. 
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Candidate 
Gene 
Existing Evidence Take 
Forward? 
EGFL6 • Codes for a member of the epidermal growth factor 
superfamily 
• Previously identified in ovarian cancer endothelial 
cells(92) 
• Widespread expression outside the colon(93) 
• Likely to be a secreted protein rather than 
transmembrane(94,95) 
No 
THSB2 • Codes for Thrombospondin-2 
• Well known to be a potent inhibitor of tumour 
growth(96) and angiogenesis(97) 
No 
HSD11B1 • Codes for the microsomal enzyme Hydroxysteroid 
(11-Beta) Dehydrogenase 1 
• Not transmembrane. 
No 
TRIB3 • Codes for Tribbles Pseudokinase 3, a negative 
regulator of NF-kappB, which sensitizes cells to 
TNF- and TRAIL-induced cellular apoptosis. 
• Has been previously implicated and studied as a 
biomarker for CRC prognosis(98), and in breast 
cancer(99). 
No 
IL6 • Codes for interleukin 6.  
• Widespread mediator of fever and acute phase 
response. 
• Well known to have systemic high levels in 
malignancies, including CRC(100). 
No 
NOTCH3 • Codes for a protein which has a role in intercellular 
communication, particularly in neuronal 
development 
• Previously implicated in CRC as a nuclear 
protein(101). 
No 
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PLXDC1 • Codes for plexin domain containing 1 protein 
• Known to be found as endothelial marker in 
glioblastomas(102). 
• One of the original TEMs, TEM7(53). 
No 
GRIN2D • Codes for the NMDA Receptor Subunit 2D 
• Has been raised as a non-endothelial candidate in 
Breast Cancer(103). 
• Upregulated in tumour cell lines in vitro(66) 
Yes 
PDGFRB • Codes for Platelet Derived Growth Factor Receptor 
Beta 
• PDGF Very well known to be tumour endothelium 
associated, so disregarded. 
No 
FZD10 • Codes for Frizzled Receptor 10 
• Previously implicated in CRC(104) 
No 
GJA4 • Codes for Connexin-37, a gap junction protein 
• Implicated in tumour cell proliferation(105).  
Yes 
WNT2 • Codes for the wingless-type MMTV integration site 
family member 2 
• WNT pathway well known in carcinogenesis(106). 
No 
LOC541471 • Predicted non-coding locus on chromosome 2 
• No literature 
•  
Yes 
LILRB4 • Codes for a member of the leukocyte 
immunoglobulin-like receptor family 
• Role identified in gastric cancer(107).  
• Appears to suppress host immune response to a 
tumour(108). 
Yes 
VASN • Codes for Vasorin 
• Known endothelial protein linked to the arterial 
response to injury(109). 
• No literature on malignancy 
Yes 
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FCGR3A • Codes for the Fc fragment of IgG receptor, low 
affinity IIIa, (CD16a) 
• Trials of the monoclonal antibody ofatumumab in 
patients with metastatic CRC, has shown response 
to be predicted by FCGR3A genotype 
expression(110). 
No 
P2RY6 • Codes for a G-protein coupled nucleotide receptor 
• Considered important in bone development, and 
implicated in the pathogenesis of 
osteosarcomas(111). 
Yes 
LINGO1 • Codes for the Leucine-Rich Repeat And 
Immunoglobulin Domain-Containing Protein 1 
• Role in axonal regeneration 
• Implicated in Parkinson’s disease 
No 
IL13RA2 • Codes for the IL13 Receptor A2 
• Function in internalisation of IL13 
• Linked with pathogenesis of adrenocortical tumours 
Yes 
LZTS1 • Codes for the leucine zipper, also known as 
putative tumour suppressor 1. 
• Implicated in multiple tumour types(112) 
• Ubiquitously expressed in normal tissues(112) 
No 
KCNJ8 • Codes for a G-protein controlled Potassium 
Channel subunit. 
• Linked to cardiac arrhythmias and 
hypotension(113). 
Yes 
SLAMF8 • Codes for a member of the CD2 family of cell 
surface proteins 
• Involved in lymphocyte activation 
No 
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Table 3 – Summary of the Literature Review of Candidate TEMs in CRC. 
 
  
PGF • Codes for placental growth factor 
• Also known as VEGF-related protein. 
• Well known to promote tumour growth, including in 
colorectal cancer(114). 
No 
MARCO • Codes for a receptor for bacteria on macrophages. 
• Not endothelially associated 
No 
OR51E1 • Codes for an olfactory receptor. 
• Potential marker of small bowel neuroendocrine 
tumours(115). 
• Also implicated in prostate cancer(116). 
Yes 
RGS16 • Codes for Regulator of G-Protein Signalling 16 
• Previously implicated in pancreatic cancer(117). 
Yes 
ADAP2 • Codes for ArfGAP with dual PH domains 2 
• Associated with an increased risk of malignancy in 
neurofibromatosis(118). 
Yes 
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3.2 VALIDATION OF NOVEL TEMs IN COLORECTAL CANCER 
Having refined the long-list of 28 candidate genes to a manageable list of 10 
candidates, the FASTA nucleotide sequences were submitted to the Roche primer 
design service, and forward and reverse primer sequences obtained, with a 
corresponding Universal ProbeLibrary Probe for ongoing real-time quantitative PCR 
(RTqPCR) validation in further biological replicates. One target, IL13RA2, was 
excluded at this stage, as no primers could be designed, leaving a final short-list of 
nine:  
LOC541471 KCNJ8 VASN 
P2RY6 OR51E1 ADAP2 
GRIN2D GJA4 RGS16 
 
Table 4 – Gene Candidates Taken Forward for Further Study 
 
Following RTqPCR, those targets with sufficiently consistent expression on the RNA 
level were submitted to immunohistochemical analysis on paraffin embedded 
sections of colorectal cancer and normal colon. 
 
3.2.1 – Real-time Quantitative PCR Validation of Gene Shortlist 
The method of real-time quantitative PCR was originally described in 1996 by Heid et 
al(119). It developed as a modification of the earlier methods of quantitative gene 
analysis(120), and reverse-transcriptase PCR(121). Early incarnations of the method 
used quantitation resulting from Sybr Green DNA dye concentrations on agarose gel, 
but the modified method utilising a TaqMan probe-based system has been shown to 
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be preferable both in terms of sensitivity and accuracy(122). The method relies upon 
an engineered probe which recognises a specific region within the DNA sequence, 
as described by the method of Higuchi et al.(123). The probe has both a fluorophore 
(or reporter) at the 5’ end and a quencher compound at the 3’ end, which prevents 
the emission of light by the fluorophore. However, when the gene sequence is 
present, the probe anneals downstream from one of the primer sites and is cleaved 
by the 5´-nuclease activity of Taq DNA polymerase. The cleavage of the probe 
liberates the fluorophore into solution. This occurs in a directly proportional 
concentration to that of the original DNA in the sample, where it can then be 
measured and quantified (Figure 3.1).  
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Figure 3.1 – The Mechanism of RTqPCR. The liberation of the reporter (‘R’) into 
solution is detected and quantified in proportion to the gene expression in the 
sample. Taken with permission from http://edoc.hu-berlin.de/dissertationen/kuner-
ruprecht-2002-07-02/HTML/Kuner-ch2.html 
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In order to further narrow the short list, RTqPCR was performed in a further biological 
replicate as described in section 2.2.1.4. On the basis of these results, only those 
candidates with confirmed expression greater than two-fold were taken forward. 
 
 
Figure 3.2 – Quantitative analysis of the relative expression of candidate genes 
between patient-matched Colorectal Cancer (CRC) and Normal Colon (NC). 
Normalised to Beta Actin. 
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This led to the shortlist being narrowed to include LOC541471, GRIN2D, OR51E1 
and KCNJ8. Further RTqPCR analysis was undertaken in five further paired 
biological replicates: 
 
Figure 3.3 – Candidate Expression in Further Biological Replicates. Normalised 
to Beta Actin. (n=5). 
 
While OR51E1, KCNJ8 and GRIN2D looked promising at this stage, there had been 
no adjustment for the degree of endothelial enrichment between the samples. 
Therefore further RTqPCR was performed with normalisation against beta actin for 
cell number, but also against PECAM to adjust for endothelial cell enrichment: 
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Figure 3.4 – Endothelial Candidate Expression. Normalised to PECAM. All 
statistical significance measured by Mann Whitney. 
 
As can be seen from Figure 3.3, the promising raw expression levels of both 
OR51E1 and KCNJ8 were negated by adjustment for endothelial enrichment. 
However, expression levels of LOC541471 (p=0.006) and GRIN2D (p<0.0001) were 
confirmed as statistically upregulated in CRC compared to patient-matched normal 
colon.  
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3.2.2 – Immunohistochemical Validation 
While RTqPCR offers validation on an RNA level for the differential expression, this 
does not always translate into expression on a protein level(124). The process of 
immunohistochemistry (IHC) depends upon the specific interaction of an antibody 
and an antigen within a histological tissue section.  Successful IHC depends upon 
two factors – the presence of the protein of interest within the tissue section, and an 
antibody that is highly specific to the target of interest. Two commercially available 
monoclonal antibodies were used for validation by IHC and Western blot. They were 
termed the 43 and 48 antibodies based upon catalogue number. However, both blots 
and IHC were unsatisfactory, with non-specific binding present using both methods. 
While neither antibody was specific enough to conclusively validate the presence of 
GRIN2D on endothelial cells, staining with the GRIN2D 48 antibody did suggest an 
endothelial pattern, alongside the non-specific staining. It was therefore concluded 
that endothelial expression was possible. Once a human GRIN2D-GST construct had 
been generated (as explained in Chapter 4), Protein was sent to Eurogentec for 
custom polyclonal serum generation in rabbits. This polyclonal serum was then 
utilised as a primary antibody in immunohistochemistry. It positively stained in 
HEK293T cells transfected to express GRIN2D-Fc (as described in Chapter 4), and 
also exhibited an endothelial expression pattern within paraffin embedded sections of 
colorectal cancer, but not in its matched controls (Figure 3.5). Unfortunately, within 
the time constraints of this project, the IHC process could not be optimised to gain 
better images than those presented, but this work has been subsequently completed 
within the group. 
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On the basis of these preliminary results obtained in histological sections of 
colorectal cancer (NHS, Birmingham, UK), GRIN2D was taken forward as a potential 
endothelial target in colorectal cancer.  
 
 
 
Figure 3.5 – Immunohistochemical Validation of GRIN2D as a Tumour 
Endothelial Marker in Colorectal Cancer. Differential staining is seen between 
control (i) and GRIN2D-expressing (ii) HEK293T cells in cytospin slides. Equally, an 
endothelial staining pattern is seen when staining in colorectal cancer (iv), but not in 
patient-matched normal colon (iii). Serum is utilised undiluted as primary antibody. 
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3.3 FUNCTIONAL CHARACTERISATION OF GRIN2D 
Available evidence suggests that endothelial specific genes are often involved in 
endothelial cell biology and angiogenesis(125,126). Having identified GRIN2D as an 
endothelial specific protein in colorectal cancer, this section describes work 
performed in conjunction with Joseph Wragg (Bicknell Group, University of 
Birmingham, UK), to outline the effects of gene knockdown on HUVEC biology in 
vitro. To ensure generalisability of the results, assays were performed on HUVEC 
isolated from three separate umbilical cords, and with two different siRNA duplexes. 
The results presented are summarised from all cord/duplex combinations for clarity of 
presentation. 
The assays were selected to quantify each stage of angiogenesis, namely cellular 
migration, proliferation and tube formation.  
 
3.3.1 – siRNA Knockdown of GRIN2D in HUVEC 
Knockdown of GRIN2D gene function in HUVEC was performed using lipofectamine 
transfection, and relative GRIN2D expression following knockdown quantified using 
RTqPCR. Duplex A achieved a knockdown of 80% of gene expression, with Duplex 
C achieving a knockdown of 65% expression on RTqPCR when compared to a 
scrambled knockdown (Figure 3.6).  
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Figure 3.6 – siRNA Knockdown of GRIN2D in HUVEC. Quantified by RTqPCR, 
normalised to Beta Actin. 
 
3.3.2 – Scratch Wound Assay 
The scratch wound assay is a well-established approach to investigate cell migration 
in vitro, especially in combination with siRNA knockdowns(127). The assay involves 
disrupting a confluent monolayer of cells in a consistent formation, then subsequently 
monitoring the closure of the wound over a number of time points.  
Measurements of the open area of a scratch wound were quantified using ImageJ 
software, and results generalised across HUVEC from three different umbilical cords. 
Due to the differences in HUVEC behaviour across cords, exact matching time points 
were inappropriate for analysis, so the start, midway closure point and end of the 
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control wound closure was used in each case, with the results summarised. siRNA 
knockdown of GRIN2D is associated with a significant impairment in cellular 
migration as measured by scratch wound closure (p<0.0001, Mann-Whitney Test).  
 
 
Figure 3.7 – Scratch Wound Assay. Quantification of wound closure by ImageJ 
software, indicating a significant decrease in closure following siRNA knockdown of 
GRIN2D compared to scrambled control (p<0.0001, Mann-Whitney Test). 
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3.3.3 – Matrigel Cellular Interaction Assay 
Matrigel contains a number of extracellular matrix proteins that have been extracted 
from Englebreth-Holm-Swarm murine sarcomas. It primarily consists of laminin, 
collagen IV, and entactin, and is considered to be a reconstituted basement 
membrane preparation(128). It also contains cellular growth factors such as basic 
fibroblast growth factor, epidermal growth factor, platelet-derived growth factor, 
insulin-like growth factor 1, transforming growth factor beta, and nerve growth 
factor(129). At 37oC, it forms a gel on which cells can be grown, and cell-cell 
interactions observed. The effect of siRNA knockdown on vascular tube formation in 
HUVEC was investigated by quantifying the number of nodes in a microscopic field, 
and the number of sprouts from each node after 16 hrs. siRNA knockdown of 
GRIN2D resulted in both a significant decrease in node formation (Mann-Whitney, 
p=0.0008), and the number of sprouts per node (Figure 3.8). These results indicated 
that knockdown of GRIN2D interferes with HUVEC cell-cell interaction, and impairs 
tube formation in vitro. 
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(i)          (ii) 
 
(iii)        (iv) 
 
Figure 3.8 – Matrigel Assay. A decrease in visible cell-cell interaction was observed 
between control knockdown (i) and GRIN2D knockdown (ii) after 16 hrs. This was 
demonstrated both in terms of the average number of nodes observed (iii) (Mann-
Whitney, p=0.0008), and the total number of sprouts per node (iv) (Mann-Whitney, 
p<0.0001 between both low number of sprouts (2 or less) and high numbers of 
sprouts (3 or more) per node.) 
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3.3.4 – Boyden Chamber Assay 
The modified Boyden Chamber Assay, also known as the Transwell migration assay 
is used to quantify cellular chemotaxis and migration in response to pro-angiogenic 
stimuli(130). Briefly, HUVEC are loaded above a porated membrane in serum 
deplete media, with enriched media beneath (Figure 3.9,i). The percentage of cells 
migrating from above to below the membrane is microscopically quantified as a 
measure of cell migration following 4',6-diamidino-2-phenylindole (DAPI) staining of 
the formalin-fixed membrane. siRNA knockdown of GRIN2D significantly impairs 
cellular migration and chemotaxis, when measured in five random fields per replicate, 
with three replicates per condition (Figure 3.9,ii). 
 
  
!)&!
(i)        
 
 
ii) 
 
 
Figure 3.9 – (i) The Modified Boyden Chamber Assay. (ii) siRNA knockdown of 
GRIN2D impairs cellular migration in HUVEC, demonstrating a significant decrease 
in cellular migration and chemotaxis with GRIN2D knockdown (p<0.001, Mann-
Whitney). 
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3.3.5 – Acumen Cell Cycle Analysis 
The Acumen™ Cell Analyser (TTP Labtech, Melbourn, Herts, UK) was utilised to 
make an assessment of the effect of siRNA knockdown of GRIN2D on HUVEC cell 
cycle and viability(131). DNA was labelled using Hoechst stain, and measured using 
405 nm laser excitation. 
 
(i)          (ii) 
  
(iii)          (iv) 
 
Figure 3.10 – Acumen™ cell cycle analysis. Images (i) and (ii) are stock images 
showing healthy and apoptosing cells respectively. Image (iii) shows the effect of a 
scrambled siRNA knockdown, and image (iv) that of GRIN2D siRNA knockdown. 
Black = Dead cells, Yellow = apoptosing cells, Green = G0/1 Phase, Orange = S 
Phase, Purple = G2/M Phase.  
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While the process of siRNA knockdown clearly affects overall cell viability, with a 
visible increase in the proportion of dead (black) cells, there was not a significant 
difference between the scrambled control siRNA knockdown and the GRIN2D 
knockdowns. It can also be seen that there was a normal proportion of mitotic (G2/M 
Phase) cells within the GRIN2D knockdown cells. In combination, this indicated that 
siRNA does not affect cell viability. 
 
3.3.6 Chapter Conclusion 
GRIN2D has been identified and validated as a putative tumour endothelial marker in 
colorectal cancer through a sequential process of endothelial cell isolation, RNA 
extraction and microarray analysis, followed by quantitative PCR and 
immunohistochemical analyses. 
 
By utilising siRNA knockdown, it has been demonstrated that a decrease in GRIN2D 
gene expression significantly decreases cellular migration, communication and 
chemotaxis, without adversely affecting cell viability or proliferation in vitro. 
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CHAPTER FOUR 
 
DESIGN AND CONSTRUCTION OF A GRIN2D-BASED 
TUMOUR VACCINE 
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4.1 TARGETING GRIN2D 
 
In order for a protein to be utilised as a vascular endothelial target for a vaccine 
based approach, it is important for there to be target-specific epitopes to stimulate an 
antibody response, which is readily accessible to the bloodstream. This chapter 
describes the process of identification of a suitable target region within the GRIN2D 
protein, and the processes pursued in order to produce an appropriate protein for use 
as a protein-based vaccine in vivo. 
 
4.1.1 – The Structure of GRIN2D 
GRIN2D is an ionotropic NMDA receptor subunit, and as such has been predicted to 
have an intracellular C-terminus, and an extracellular N-terminus(59). Between these 
termini, there are predicted to be four transmembrane regions, the second of which 
forms the ion channel in conjunction with three other subunits. This has been 
described as a putative structure for the NR2 subunits, with analogous structures in 
the AMPA glutamate receptor confirmed by fluorescence-detection size-exclusion 
chromatography(132). However, this structure has not been confirmed for GRIN2D. 
Bioinformatic prediction suggested that both the N- and C- termini were extracellular, 
and hence targetable (Figure 4.1), in contrast to the published proposed structure. 
Evidence suggests that the structure of the amino-terminal domain of each NR2 
subunit defines the behavior of the NMDA receptor(59), and therefore it was 
considered that this region should be focused upon when identifying a targetable 
sequence. This decision also negated any concerns regarding the intra- or extra-
cellular position of the carboxyl-terminal domain. 
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 Figure 4.1 – Bioinformatic Prediction of Transmembrane regions of GRIN2D. 
Suggestive of both an extracellular N- and C-Terminus (Centre for Biological 
Sequence Analysis, The Technical University of Denmark, CTU.) 
 
4.1.2 – Identification of an Appropriate Target Sequence 
Clinical response to antibody-directed therapy, with minimal side-effects, depends on 
the identification of an antigen which is highly specific to the target tissue of 
interest(133). However, this specificity must also extend to the region of the target 
molecule of interest, if off target effects are to be avoided. 
The GRIN2 subgroup has molecular regions that are highly conserved and unique 
compared to other subgroups. Specifically, the transmembrane region and ligand-
binding regions are highly conserved, both across species and between GRIN2 
subtypes. The greatest variability occurs in both the N- and C- terminal regions(134). 
As previously stated, the published consensus errs towards the C-terminal region 
being intracellular, with it therefore being inaccessible to circulating immune cells. 
Focus was therefore concentrated on the N-terminal region of the GRIN2 family. 
Multiple sequence alignment was performed, and an 81 amino acid sequence was 
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identified which was unique to human GRIN2D, and an equivalent 78 amino acid 
sequence in mouse GRIN2D, corresponding to the same region. These target 
sequences underwent comparative sequence analysis using the Protein Basic Local 
Alignment Search Tool (BLASTp) tool from NCBI to ensure there was no significant 
sequence homology with any other human or murine protein, thereby decreasing the 
likelihood of any off-target effects of any future targeted therapy. Sequence alignment 
with the other members of the GRIN2 subgroup were also performed in human and 
mouse to ensure there was no sequence homology within the target region of interest 
(Figure 4.2). 
 
While the primary amino acid sequence is important in predicting specific 
immunological reactions, the secondary structure also contributes significantly. 
Peptide sequences inevitably form different secondary structures to the full-length 
protein, and efforts were made to predict the secondary structure of the N-terminal 
sequence of human GRIN2D to ensure that some of its secondary structure 
remained. These indicated that the helical structure of the predicted peptide was 
consistent with the same segment of the predicted full-length protein (Figure 4.3).  
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Figure 4.2 – Human and Murine Sequence Alignment of GRIN2 Subgroup. 
Unique, extracellular sequences within the human and mouse amino acid sequences 
for GRIN2D are indicated in yellow..  
  
Human 
  
Base  1 
GRIN2D      MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFS--
GRIN2A      ----------MGRVGYWTLLVLPALLVWRGPAPSAAAEKG-------PPALNIAVMLGHS 
GRIN2B      ----MKPRAECCSPKFWLVLAVLAV-----SGSRARSQKS-------PPSIGIAVILVGT 
GRIN2C      ---MGG---ALGPALLLTSLF----GAWA--------GLGPGQG---EQGMTVAVVFSSS 
                               *                   .          : :*:::    
Base  60    81 
GRIN2D      G--PAYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVV 
GRIN2A      H-DVTERELRTLWGP---EQAAGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLV 
GRIN2B      SDEVAIK---DAHEK---DDFHHLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVV 
GRIN2C      G--PPQAQFRARLTPQ---SFLDLPLEIQPLTVGVNTTNPSSLLTQICGLLGAAHVHGIV 
                                     :  .   : :* ::* *:: ::* *:.  :::*:* 
Base  120 
GRIN2D      FEDDSRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIF
GRIN2A      FGDDTDQEAVAQMLDFISSHTFVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVML 
GRIN2B      FADDTDQEAIAQILDFISAQTLTPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVML 
GRIN2C      FEDNVDTEAVAQILDFISSQTHVPILSISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLF 
            * *:    *:* :***:*::*  **:.: **:::::: *:  * *:*:* * :**  *:: 
 
Mouse 
Base  1!
GRIN2D      MRGAGGPRGPRGPAKMLLLLALACASPFPEEVPGPGAAGGGTGGARPLNVALVFS--GPA 
GRIN2A      ----------MGRLGYWTLLVLPALL----VWHGPAQNAAAEKGTPALNIAVLLG-HSHD 
GRIN2B      ----MKPSAECCSPKFWLVLAVLAV---------SGSKARSQKSAPSIGIAVILVGTSDE 
GRIN2C      ---MGGA---LGPALLLTSL------------LGAWAGLGAGQGEQAVTVAVVFGSSGPL 
                               *                    .  .   : :*:::   .   
Base  60   78 
GRIN2D      YAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDDS 
GRIN2A      VTERE-LRNLWGPEQATGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDT 
GRIN2B      VAI----KDAHEKDDFHHLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVLADDT 
GRIN2C      QAQARTRLTPQ---NFLDLPLEIQPLTIGVNNTNPSSILTQICGLLGAARVHGIVFEDNV 
       :                  :  .   : :* ::* *:: ::* *:.  :::*:*: *:  
 
GRIN2D       RAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLEE 
GRIN2A       DQEAVAQMLDFISSQTFIPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQD 
GRIN2B       DQEAIAQILDFISAQTLTPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEE 
GRIN2C       DTEAVAQLLDFVSSQTHVPILSISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLFKVLEE 
             :;:*:* :***:*:**  **:.: **:::::: *:  * *:*:* * :**  *::::::: 
* - full alignment, : - Alignment in 3 of 4 sequences, ; - alignment in 2 
of 4 sequences. 
 
!
!*$!
(i)                     (ii) 
 
iii) 
 
 
 
 
 
 
 
Figure 4.3 – Bioinformatic Prediction of the Secondary Structure of the N-
Terminal Domain of GRIN2D. Calculated from (i) the full-length human GRIN2D 
sequence, and (ii) from the 81 amino acid N-terminus peptide to be taken forward (ii) 
by PSIPRED software (UCL Dept. of Computer Software). An alternate prediction 
giving a three-dimensional representation of the GRIN2D N-Terminus peptide is also 
shown (iii) (http://swissmodel.expasy.org). Indications are of significant homology 
between the two entities in terms of secondary structure. 
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4.2 EXPRESSION OF GRIN2D FUSION PROTEINS 
In order to take GRIN2D forward as a TEM in colorectal cancer, it was necessary to 
generate protein based upon the identified human and mouse target sequences. The 
generation of conjugate proteins was favoured in this process, as protein ‘tags’ can 
be used for downstream purification, and can also be useful in identifying proteins in 
analytical processes where no reliable antibody exists, as is the case with GRIN2D.  
  
4.2.1 The GRIN2D Target Sequence 
In order to produce the target regions of human and mouse GRIN2D, it was 
necessary to generate sufficient corresponding DNA to enable transfection into 
bacterial or mammalian expression hosts. For human GRIN2D, initial attempts were 
made to achieve this through PCR amplification from complementary DNA derived 
from a neuronal cell line, SHSY5Y (Nagy Lab, University of Birmingham, UK), which 
had demonstrated high levels of expression of GRIN2D when quantified by RTqPCR. 
However, despite numerous attempts, with varying concentrations of DMSO and 
Magnesium, amplification failed, presumably as the sequence is highly ‘GC’ rich. 
Therefore, the sequence was designed to provide the in-frame message for 
subsequent expression in both the pcDNA3 and pGEX2T vectors, and was 
commercially synthesised (Integrated DNA Technologies, Coralville, Iowa, USA) with 
the BamHI and EcoRI restriction sites in place:  
,-./0#1!!
!
!!"#2/!
--345534-5-5--5-55--4--55555-5--55545----5555-5433-34-54-54-54
-54--5-54--554-5-553-555-44555--3--3--5-55----55---5----55--4-
--555--5--5--5545--5----5-5--55-545335-4--5-545-4-44545----555
-5-435-5--55-3--5--535-554---555--55-4--5--5--5--4-5-53-555---
533-33445!!
!!!!!!!!!!!$%&./!
!
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The DNA was received within a transport Vector, the IDTSmart-Amp Vector: 
 
Figure 4.4 – Vector Map of the Human GRIN2D-IDT Construct. 
 
An equivalent sequence was synthesised for mouse GRIN2D, and received within 
the same transport vector: 
6-./0#1!
!
!"#2/!
--345534-5-5--5-55--4--55555-5--55545----5555-5433-34-54-44-54
-54--5-54--5-4-5-553-555-44555--3--3--4-55----55---5-5--55--5-
----535---5----5-5--55-545335-4--5-54--45445454--555--5-435-5-
-55-3--5--5-5-544---555--55-4--5--5--53-4-5-53-555---533-33445!
$%&./!
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4.2.2 – Expression of hGRIN2D-Fc and mGRIN2D-Fc Fusion Protein 
Informed by the work of Zhuang et al.(135), an Fc-fusion protein was chosen as the 
primary conjugate protein for production. The Fc tag is formed of a 230 amino acid 
sequence encoding for the Fc chain of human IgG1. The Fc tag enables efficient 
purification by the use of Protein A affinity chromatography(136), and has also been 
shown to increase the solubility and stability of the fusion partner protein both in vitro 
and in vivo(137). For our particular purpose of the utilisation of Fc-fusion proteins as 
therapeutic tumour vaccines, the tag also enables interaction with the Fc receptors of 
circulating immune cells, thereby increasing the immune response against the fusion 
partner(138). 
The pIgG vector (pcDNA3.Fc) is a vector previously constructed within the Bicknell 
Laboratory whereby the constant region of the Fc Heavy chain has been cloned into 
the pcDNA3 vector using the NotI and XbaI restriction sites, enabling flexible 
positioning of the fusion partner protein. It has previously been shown to be a high 
copy vector in this application(135). It also codes for the CMV and SV40 promoters, 
enabling protein expression in mammalian cell lines. The full construct post-insertion 
of GRIN2D can be seen in Figure 4.5. When generating the construct for human and 
mouse GRIN2D, the pre-engineered restriction sites BamHI and EcoRI were utilised. 
GRIN2D was digested from amplified, purified DNA from competent E.coli using a 
double digest technique. The ends were then dephosphorylated with antarctic 
phosphatase, and then ligated into the pIgG vector using the same restriction sites at 
both 1:3 and 1:5 vector to insert ratios using T4 ligase. Both ratios were successful, 
and presence of the insert was confirmed on an agarose gel following re-digest of 
plasmid DNA from re-transformed E.coli (Figure 4.6), and was also sequence verified 
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by the functional genomics facility at the University of Birmingham. Data was 
analysed using Sequencher software (Gene Codes Corporation, Ann Arbor, USA). 
 
 
Figure 4.5 – Representative Vector Map of the pIgG-GRIN2D Vector. Separate 
constructs were made for human and mouse GRIN2D-Fc by the same process. The 
resulting construct was a GRIN2D-Fc fusion protein with the Fc tag at the C-terminal 
end of the target GRIN2D sequence. 
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Figure 4.6 – Restriction digest of pIgG-GRIN2D. 1% Agarose gel of digested 
transformant bacterial colony DNA. The ladder used is a GeneRuler™ 1kb ladder. 
Lane 1 – 1kb Ladder. Lane 2 – undigested vector. Lanes 3-7 - 1:3 vector to insert 
ratio. Lanes 8-12 - 1:5 vector to insert ratio. 6kb bands correspond to the vector, with 
the digested insert corresponding to the expected size of 243 bases in lanes 3-12. 
 
Following verification of the respective human and mouse GRIN2D sequences, PEI 
transfection of HEK293 cells was performed to induce protein expression. Care had 
been taken in the design of the target sequence to ensure that a signal peptide was 
present, to facilitate secretion of the fusion protein from the cells. The presence of the 
signal peptide was confirmed using SignalP-4.1 prediction software(139). 
HEK293 cells are derived from the human embryological kidney, transfected with 
fragmented adenovirus 5 DNA. This provides the cells with the ability to synthesise 
large quantities of peptide when transfected with a suitable vector, such as pcDNA3 
and its derivatives(140). 
Trial transfection was performed on a small scale. Trial pull-down of hGRIN2D-Fc 
was also performed using 100 µl Protein A beads. This process was analysed by 
western blot for the presence of Fc-fusion protein of the appropriate size. In the 
!
!
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!
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absence of specific anti-GRIN2D antibodies, an anti-Fc blot was used to confirm 
expression by proxy:  
(i)          (ii) 
 
Figure 4.7 – Trial GRIN2D-Fc Production and Purification.  
Corresponding Coomassie Stain (i) and anti-Fc Western Blot (ii) of 12% SDS-PAGE 
Gel. Lane 1 – Purified Human Fc. Lane 2 – Optimem. Lane 3 – Secreted Media. 
Lane 4 – Purified GRIN2D-Fc. Lane 5 – Depleted Media. Predicted size of hGRIND-
Fc = 34 kDa; Fc = 26 kDa 
 
Once the process had been successful on a small scale, twenty 15 cm plates of 
HEK293 cells were transfected, and incubated with low serum media. Media was 
collected every other day for 21 days, and the resultant volume passed through a 
Protein A column. Protein A has a high affinity for the Fc fragment of human IgG, 
enabling an Fc fusion protein to be effectively purified by exposure to sepharose 
!"++!
bound to protein A(141). Elution from the column was carried out at pH 3.0, so the 
resulting eluate was pH adjusted using TRIS-HCl pH 8.5 to pH 6.5, a point which is 
both unlikely to denature the protein, and at which the protein is unlikely to precipitate 
out of solution, as it is away from the predicted isoelectric point (pI) of the GRIN2D-
Fc fusion protein as calculated by the Expasy ‘compute pI/Mw tool’(142). For both 
hGRIN2D-Fc and mGRIN2D-Fc, the pI was predicted to be pH 8.53. The sample was 
sterile filtered, and stored at 4oC. The concentration of the purified protein was 
calculated by Pierce BCA Protein Assay, and the identity of the protein again verified 
by SDS PAGE followed by Coomassie stain and western blot.  
 
Figure 4.8 – Large-scale Purification of hGRIN2D. Coomassie stain of 12% SDS 
PAGE Gel. Lane 1 – Purified Human Fc. Lane 2 – Affinity purified GRIN2D-Fc. Lane 
3 – Secreted Media. Lane 4 – Depleted Media. Predicted size of hGRIN2D-Fc = 34 
kDa; Fc = 26 kDa. 
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Following Protein A column purification of mGRIN2D, it was noted that there was a 
contaminant Fc-fusion protein in the final eluate, which had not been represented in 
the secreted media: 
(i)                       (ii) 
 
Figure 4.9 – Contaminant Fc-fusion Protein. (i) Coomassie Stain. Lane 1 – 
PageRuler Plus Ladder, Lane 2 – Optimem, Lanes 3-6 – secreted media, Lane 7 – 
‘Purified’ mGRIN2D-Fc. (ii) anti-Fc Western Blot of Lane 1 – Fc, Lane 2 - column 
eluate Contaminant band >100 kDa on Coomassie corresponds to upper band on 
anti-Fc blot. 12% SDS-PAGE Gel. 
 
As this protein was confirmed as an Fc-fusion protein on western blot, and would 
potentially confound any future assays performed with the protein, the sample 
underwent size exclusion chromatography (SEC). SEC is a method by which proteins 
of different molecular weights can be separated by the use of a column, which allows 
passage at different rates depending on size. The column consists of Dextran bound 
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to highly cross-linked porous agarose beads, which permits passage of larger 
proteins more easily than small proteins, which are hindered by the smaller pores in 
beads. This allows the collection of differential fractions of column-flow-through, 
enabling purification of mGRIN2D-Fc, and exclusion of the contaminant protein. The 
flow through is analysed by UV absorbance, allowing quantification of protein in each 
fraction (Figure 4.10).  
 
 
Figure 4.10 – UV Absorbance analysis of SEC for mGRIN2D-Fc. The deflection at 
150 ml represents the larger, contaminant protein, with the major deflection from 180 
ml to 230 ml representing mGRIN2D. The volume within this major deflection was 
collected in 5 ml fractions 
 
All fractions expected to contain mGRIN2D-Fc were analysed by SDS-PAGE (Figure 
4.11), then those confirmed to contain mGRIN2D were pooled and concentrated 
using a VivaSpin® column. Protein concentration was then confirmed by BCA Protein 
Assay, and the sample was sterile filtered and stored at 4oC. 
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Figure 4.11 – Fractions Collected from SEC for mGRIN2D-Fc.  
12% SDS-PAGE Gel, Coomassie Stain. Expected size for mGRIN2D-Fc = 33 kDa 
 
4.2.3 – Expression of GST-hGRIN2D and GST-mGRIN2D Fusion Protein 
While Fc-conjugate protein was desirable for some applications, the presence of the 
Fc-tag would also complicate production of polyclonal antisera against the N-
terminus of GRIN2D, as large quantities of human Fc-specific immunoglobulins 
would result, and confound future immunohistochemistry. Efforts were made to 
cleave off the Fc-tag by the use of Papain, but this was unsuccessful. Therefore, the 
Glutathione S-Transferase (GST) Gene Fusion System (GE Healthcare, Little 
Chalfont, UK) was utilised to provide a fusion protein with an alternate tag, which 
would not confound IHC in the same way. The pGEX expression vectors available 
within this system code for GST from Schistosoma japonicum. As GST is a bacterial 
enzyme, it would not be present on human histological slides, and so a polyclonal 
serum derived from this protein could be used without purification.  
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    The pGEX vector family is large, but pGEX-2T was chosen for subsequent 
expression because of the presence of both BamHI and EcoRI sites within the 
multiple cloning site, and the close proximity of the STOP codon to EcoRI, thereby 
minimising the extra amino acids appended to GST-GRIN2D during subsequent 
expression. The pGEX vectors possess the tac promoter, and as such are active in 
bacteria, rather than in mammalian cells as is the case with the pIgG vector. A 
bacterial expression system has the advantage of relatively high yield over a shorter 
period of time than a mammalian system(143), but bacteria lack the ability to perform 
post translational modification of generated peptides, which can potentially affect 
their secondary, tertiary and quaternary structures(144). Bioinformatic prediction did 
not identify any glycosylation sites or potential disulphide bonds within the target 
sequence of mouse or human GRIN2D, so bacterial expression was considered 
appropriate. The tac promoter system exists in a repressed state due to the presence 
of the lac repressor, and therefore requires induction by isopropyl-β-galactosidase 
(IPTG) to achieve protein expression(145). IPTG is a molecular mimic of allolactose, 
a lactose metabolite, which triggers transcription of the lac operator, and deregulation 
of the tac system. 
    The human and mouse GRIN2D constructs synthesised by IDT were once again 
utilised, and ligated into the pGEX2T vector utilising the BamHI and EcoRI restriction 
sites, verified by Agarose Gel analysis, and sequence verified as previously 
described.  
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Figure 4.12 – Vector Map of the pGEX2T-hGRIN2D Vector. Utilised for bacterial 
expression of GST-fusion protein.  
 
Following sequence verification, BL21 E.coli were transformed with the pGEX2T-
GRIN2D vector. BL21 E.coli are highly efficient, competent cells, which allow routine 
expression of non-T7 promoter based plasmids(146). Following transformation, trial 
induction and culture was performed on a small scale. 10 ml samples of cultured 
bacteria were collected at various time points, and analysed by SDS-PAGE. 
Upregulated production of a protein band between 25 and 35 kDa was maximal at 4 
hrs post-induction. Pull-down of this protein utilising glutathione sepharose beads 
was also successful (Figure 4.13). 
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Reserved, uninduced transformant bacteria from this process were cultured and 
stored as a stock culture for subsequent expressions. Following optimisation, large-
scale protein production was performed utilising 2 litres of bacterial culture. Stock 
culture was incubated for 2 hrs, until an OD600 of 0.6 was reached. Then induction 
with 1 mM IPTG was performed and the culture further incubated for 4 hrs. The 
culture was then collected, spun down, and the bacterial pellet lysed using a 
sequential freeze/thaw cycle at -80oC, and mild sonication in a lysis buffer containing 
DTT and protease inhibitors to reduce the chances of protein denaturation or 
aggregation. The bacterial lysate was then incubated with 1 ml of glutathione 
sepharose beads for 2 hrs. Elution was performed with 1 ml of 30 mM glutathione 
sepharose at pH 8.5. The predicted pI of GST-GRIN2D is 7.53, but fortunately, 
protein aggregation was not an issue at pH 8.5. However, interestingly, any greater 
volume of elution buffer resulted in aggregation of the protein within the eluate, 
independent of pH. Eluate from this process contained glutathione, which interfered 
Figure 4.13 – Isolation of GST-GRIN2D 
from Bacterial Lysate. 12% SDS PAGE 
Gel, Coomassie Stain.
Lane 1 – Bacterial Cell Lysate 
Lane 2 – Purified GRIN2D-GST Protein 
following incubation with glutathione 
sepharose beads. 
Predicted size GST-GRIN2D = 34 kDa
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with all attempted protein quantification assays. The eluate was therefore buffer 
exchanged using a PD10 column and quantified. The sample was placed into 
storage buffer consisting of 50mM MES at pH 5.5, with 150 nM NaCl, a point further 
from the pI of the produced protein, thereby decreasing the risk of aggregation during 
storage. 
Bands apparent on SDS-PAGE gel fall below not only the expected size of GRIN2D-
GST, but was also not the size of the GST tag alone. To ensure that this band 
represented the expected product, plasmid DNA was extracted from the transformed 
BL21 bacteria and sent for sequencing. This confirmed the presence of both the GST 
tag and the DNA for mouse or human GRIN2D within the plasmid, increasing the 
likelihood of this protein being the expected compound. Mass spectroscopy was then 
performed, which indicated that the GRIN2D component of the fusion protein was 
being cleaved early within the sequence, presumably by a bacterial peptidase, with 
only a short fragment remaining as the fusion protein. Further validation work has 
shown this short fragment as sufficient to act as an antigen in both ELISA and IHC. 
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CHAPTER FIVE 
 
INVESTIGATING GRIN2D AS A TUMOUR 
ENDOTHELIAL MARKER IN A MURINE 
COLORECTAL CANCER MODEL 
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5.1 GRIN2D AS A TEM IN MURINE COLORECTAL TUMOURS 
While GRIN2D represented a potential endothelial marker in colorectal cancer, with 
anti-angiogenic effects demonstrated in vitro, translation of this potential required in 
vivo studies. This chapter describes the establishment of a murine vaccine model 
utilising recombinant GRIN2D as the basis for a vaccine. Then, the effects of this 
novel vaccine upon in vivo angiogenesis and colorectal cancer growth are also 
described, utilising the subcutaneous sponge and subcutaneous tumour models.  All 
protocols were performed at  
 under the Project License 40/3339 held by Roy Bicknell. A personal 
license (number 70/25131 - subsequently transferred to the electronic license 
system, with the designation I350D34BB) was gained to allow personal performance 
of animal work. 
To ensure transferability of GRIN2D into murine experiments, a pilot study was 
performed utilising subcutaneous growth of CT26 colorectal cancer cells in Balb/c 
mice. A previous protocol performed within the Bicknell laboratory by Joseph Wragg 
had established the optimum cell number to be implanted within a subcutaneous 
tumour model in 4T1 cells was 1x105. This number was based on the length of time 
required for tumour establishment, and also the rate of subsequent tumour growth to 
allow adequate observation before the protocol end-point was reached. Therefore, 
1x105 CT26 cells were injected into the flank of balb/c mice, allowed to establish for 
one week, then observed for a further two weeks, until the maximum permissible size 
of 2 cm3, or tumour ulceration was observed. Tumours from treated mice and tissues 
from normal control mice were isolated and analysed for presence of GRIN2D. 
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5.1.1 – The CT26 Cell Line 
The CT26 cell line was originally generated in 1975 through chemical induction of 
rectal malignancy by intrarectal injection of N-nitroso-N-methylurethane(147). It was 
characterised as an undifferentiated, grade IV malignancy in its original host, a 
female balb/c mouse. It subsequently underwent repeated subcutaneous 
transplantation, with 70-100% of subsequent tumour transplant recipients developing 
metastases, most frequently within the lungs. It has become an established cell line 
in colorectal cancer research with metastases corroborated in both subsequent 
subcutaneous models(148), and in an orthotopic model(149). Due to its reliability, 
rapid growth, and the potential for metastases, it was taken forward as the cell line of 
choice. 
 
5.1.2 – Isolation of Murine Endothelial Cells 
To determine the endothelial specificity of GRIN2D in normal balb/c murine tissues, 
and in subcutaneous CT26 tumours, it was necessary to isolate endothelium from 
tissue bulk. This was performed using magnetic Dynabeads® which had been 
conjugated to anti-mouse-PECAM-1 antibodies. Following tissue homogenation 
using collagenase type 1, the sample was incubated with the antibody-conjugated 
Dynabeads®, and separated from the tissue bulk using a magnet within a 15 ml 
centrifuge tube. Isolation efficiency was assessed using RTqPCR, measuring 
differential expression of PECAM levels between the endothelial cell fraction and 
tissue bulk fraction, normalised to beta-actin.  
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5.1.3 – The Expression Profile of GRIN2D in Murine Tissues and Colorectal Cancer 
For further murine experimentation to be considered safe, an expression profile of 
GRIN2D within the normal murine tissues was established to ensure off-target effects 
of therapy could be predicted. Further RTqPCR was performed to ascertain relative 
expression of GRIN2D in gross terms, using beta-actin as a housekeeper gene, and 
in terms of endothelial specificity by using PECAM-1 as housekeeper, then adjusting 
for isolation efficiency. When considered in the endothelial compartment, GRIN2D 
was highly overexpressed in multiple biological replicates of CT26 colorectal 
carcinoma, when compared to normal body tissues. When tissue bulk was analysed, 
this specificity was lost, with high levels of expression within the brain, as would be 
expected, but also to a degree in the lung (Figure 5.1).  
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(i) 
 
(ii) 
 
 
Figure 5.1 – Expression of GRIN2D in Murine Tumours and Tissues.  
(i) Expression in the non-endothelial cell fraction of body tissues and tumours, 
normalised to beta actin; (ii) Relative GRIN2D expression in endothelial cell isolates, 
normalised to Beta actin, and adjusted for endothelial isolation efficiency 
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5.2 THE EFFECT OF A GRIN2D-FC PROTEIN VACCINE IN MURINE MODELS OF 
ANGIOGENESIS AND COLORECTAL CANCER 
 
Previous work by the Bicknell group has shown that protein-based vaccination of 
Robo4, a tumour-specific endothelial cell marker in lung cancer, can lead to impaired 
tumour growth in a subcutaneous murine Lewis lung carcinoma model(135). 
Therefore, it was possible that this method may be applicable utilising GRIN2D as an 
endothelial-specific tumour marker in Colorectal Cancer. This section describes the 
investigation of such a vaccine model, and its effect on physiological angiogenesis 
and subcutaneous tumour growth. 
 
5.2.1 – Establishment of a Murine GRIN2D Vaccine Model 
To pursue the project goal of investigating a vaccine-based approach to colorectal 
cancer targeting, a murine protein-based vaccination model was established. Fc-
fusion proteins of both human and mouse GRIN2D were taken forward as antigens. 
By vaccinating with either a non-self (human) and self (antigen), differential immune 
responses could also potentially be observed. Non-self antigens mirror infectious 
disease based vaccines, where the antigens are viral or bacteria components. 
Vaccination with self-antigens is analogous to products such as OncoVax™, which 
utilises individual patient tumour cells in a vaccination strategy.  
In order to vaccinate against a self-antigen, it is necessary to evade the innate 
mechanisms for avoidance of auto-immunity, by breaking immune tolerance - a 
phenomenon controlled by regulatory T-cells(150). Current investigation into 
mechanisms for breaking of immune tolerance in humans has taken two approaches. 
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The first is direct infusion of immune antigen-presenting cells, and the second, more 
established route is co-vaccination with an adjuvant which is highly 
immunogenic(151).  
Freund’s adjuvant was selected as a vaccine partner to GRIN2D. It is essentially 
paraffin oil containing mannide mono-oleate as a surfactant, with dried and 
inactivated mycobacterial components (Freund’s complete adjuvant, FCA) or without 
mycobacteria (Freund’s incomplete adjuvant, FIA)(152). FIA induces the innate 
immune system, and stimulates cytokine release(153), whereas, in addition, FCA 
enhances antigen uptake by antigen presenting cells. 
Utilising this approach, mice received 50 µg of human or mouse GRIN2D-Fc fusion 
protein subcutaneously with 100 µl of Freund’s adjuvant at two-week intervals. FCA 
was utilised at Day 0, and FIA at Day 14. Serum was collected via a tail vein bleed on 
Days 0 and 14, with a terminal cardiac bleed under general anaesthetic performed on 
day 28 (Figure 5.2). An equivalent control group of mice received 50 µg of human Fc 
only with adjuvant, in place of the fusion protein. ELISA was performed to quantify 
GRIN2D-specific antibody titers along the time course of the protocol, and to identify 
the isotypes of the induced antibodies from each protocol.  
  
!""&!
 
Figure 5.2 – GRIN2D Vaccination Protocol 
Following immunisation of mice with human GRIN2D-Fc, a significant increase in 
specific antibodies to hGRIN2D was detected (P<0.001, Mann-Whitney test), with 
IgM antibodies predominating (Figure 5.3). When the immunisation was performed 
with mouse GRIN2D, the immune response was predominated by IgG1 and IgG2b, 
indicating a Th-2 T-cell response, consistent with immunisation(76). Importantly, 
there was no evidence of a significant difference in antibody response to the Fc 
component of the vaccine, when measured by ELISA (p=0.379, Mann Whitney). 
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Figure 5.3 – Antibody Response to GRIN2D-Fc Vaccination in Balb/c Mice. 
While both immunisation with human and mouse GRIN2D elicits a highly significant, 
specific antibody response (p<0.001 Mann-Whitney), immunisation with hGRIN2D is 
associated with a predominantly IgM response, with mGRIN2D immunisation 
resulting in an IgG1 and IgG2b predominant response.  
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5.2.2 – The Effect of GRIN2D Vaccination on Physiological Angiogenesis 
As knockdown of GRIN2D expression in HUVEC had been shown to compromise 
angiogenesis in vitro, these effects were investigated in vivo using the murine 
subcutaneous sponge assay, a validated technique for studying physiological 
angiogenesis(154). At day 28 of the GRIN2D vaccination protocol, instead of cardiac 
bleed, treatment and control mice underwent surgical implantation of subcutaneous 
sponges into the flank. Basic Fibroblast Growth Factor (bFGF) was injected into the 
sponge on alternate days for 2 weeks (Figure 5.4). 
 
Figure 5.4 – Combined Protocol of Vaccination and Subcutaneous sponge 
assays 
 
The sponges were then excised, fixed in formalin, embedded in paraffin, sectioned 
and stained using haematoxylin and eosin. This allowed a gross quantitative analysis 
of vascular invasion between groups by the analysis of the sponge using ImageJ 
software (National Institutes of Health, Bethesda, USA). This was achieved by 
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creating a binary mask image of the entire sectioned sponge, and quantifying the 
invaded proportion relative to the blank, uninvaded portion. Random microscopic 
fields at 10x magnification were then assessed, and vessels further quantified at this 
cellular level.  
Following vaccination with hGRIN2D-Fc, there was no significant change in the 
vascular invasion or number of visible vessels per field of sponge. However, following 
vaccination with mGRIN2D-Fc, a significant decrease in both sponge invasion 
(p=0.0026) and vessel density (p<0.0001) was observed (Figures 5.5 and 5.6).  
 
 
Figure 5.5 – Sponge Vascular Density. A significant decrease in sponge vascular 
density was observed following mGRIN2D-Fc Vaccination compared to Fc control 
(p<0.001, Mann Whitney), but not following hGRIN2D-Fc Vaccination. n = 6 sponges 
per group, and 5 random fields per sponge. Haematoxylin and Eosin Staining. 
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Figure 5.6 – Macroscopic Evaluation of Sponge Assay. Paraffin embedded 
sponges were stained with Haematoxylin and Eosin, imaged, and reduced to a binary 
mask using ImageJ software, followed by quantification.  Vaccination with mGRIN2D-
Fc resulted in a significant decrease in sponge invasion compared to Fc controls 
(p=0.0026, Mann-Whitney), where no significant decrease was observed following 
vaccination with hGRIN2D-Fc (p=0.347, Mann-Whitney)  
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5.2.3 Establishment of a Murine Subcutaneous Colorectal Cancer Model 
The CT26 murine colorectal cancer cell line was selected for ongoing study. To 
enable real-time in vivo monitoring of tumour growth and potential metastases, the 
cell line underwent lentiviral transfection with the MSCV-Luc plasmid (88). This 
protocol had been optimised, and the CT26-Luc cell line validated within the Bicknell 
Laboratory by Joseph Wragg. The optimum cell number to be utilised within this 
model based on length of tumour establishment and rate of growth was determined 
from previous experiments using 4T1 breast cancer cells as 1x105. Over 3 weeks, 
this cell number had produced a tumour suitable for future histological analysis, 
without becoming overly burdensome for the experimental animal. Tumour growth 
was monitored by routine calliper measurement, and by use of the In Vitro Imaging 
System (IVIS) within the BMSU. The IVIS (PerkinElmer, Walton, MA, USA) is an 
integrated system allowing real-time, non-invasive imaging while maintaining 
experimental animals under general anaesthetic. It is able to quantify the 
bioluminescence emitted by CT26-Luc cells, giving an objective measure of growth, 
although it relies upon viable cells to produce bioluminescence(155), which will not 
account for a large tumour with a necrotic core. To support absolute quantitation, the 
system measures the ‘dark charge’ of the platform during downtime and subtracts 
this from the total bioluminescence. To facilitate visualization, D-luciferin was injected 
intraperitoneally at a dose of 30 mg/kg body weight. Images were taken every minute 
for 25 mins following luciferin injection to ensure peak bioluminescence was 
measured on each day. This is important as the kinetics of luciferase can vary day-
to-day, introducing error to results(155). Tumours were monitored until ulceration 
occurred or the tumour mass exceeded 2 cm3, whichever was sooner. Tumours 
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followed a standard growth curve, with little inter-tumour variability (Figure 5.7,i). The 
end points of excessive tumour growth and potential ulceration were increasingly 
encountered at 21 days post tumour injection. At the end point of the protocol, the 
experimental animals again underwent intraperitoneal injection of D-luciferin, 
followed by resection of the primary tumour. The peritoneal and thoracic cavities 
were opened, and IVIS imaging performed. No evidence of metastasis was noted on 
bioluminescent imaging (Figure 5.7,ii). Subsequent haematoxylin and eosin staining 
of multiple body organs also refuted the presence of metastases in this model. 
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(i) 
 
(ii) 
 
 
Figure 5.7 – The CT26-Luc Tumour Model. i) A typical growth curve of 
subcutaneous CT26-Luc colorectal cancer cells in Balb/c mice. ii) Typical IVIS 
imaging of tumour at day 21 post implantation, and the absence of bioluminescent 
evidence of metastasis following primary tumour resection. 
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5.2.4 The Effect of GRIN2D Vaccination on Subcutaneous CT26 Tumour Growth 
Once reliable growth of subcutaneous CT26-Luc tumours had been established, and 
the vaccine method shown to induce a specific immune response to GRIN2D, the 
protocols were combined (Figure 5.8).   
 
Figure 5.8 – Protocol for GRIN2D Vaccination Followed by Subcutaneous CT26 
Tumour Growth Monitoring. 
 
Following immunisation of mice with human GRIN2D-Fc, there was no difference in 
the growth rate of subcutaneous CT26 tumours to the control group. However, 
following mouse GRIN2D-Fc vaccination, a significant decrease in tumour growth by 
calliper measurement was observed (p=0.004, Mann-Whitney) (Figure 5.9). This was 
corroborated by analysis of excised tumour weight (p=0.0274) and IVIS monitoring of 
tumour growth. Interestingly, RTqPCR quantification of GRIN2D expression within 
the endothelial compartment of the excised tumours endothelial cells demonstrated a 
5.5-fold upregulation of expression within the mGRIN2D-Fc treated group compared 
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to controls, when adjusted for endothelial isolation efficiency (p=0.0069, Mann-
Whitney). 
i)                     ii) 
 
iii)            iv)
 
Figure 5.9 – Vaccination with mGRIN2D-Fc Significantly Decreases 
Subcutaneous CT26 Tumour Growth, but Vaccination with hGRIN2D-Fc Does 
Not. Reduction in growth with GRIN2D-Fc is confirmed by (i) calliper measurement, 
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post-resection tumour weight (ii) and size (iv), and throughout the experiment by IVIS 
imaging (iii). Mann Whitney U-Test to determine significance. n=6 per group. Mouse 
3 in the mGRIN2D-Fc treated group died during IVIS imaging, so was not included in 
statistical analyses. 
 
Vascular density was quantified in excised subcutaneous CT26-Luc tumours, 
indicating a significant decrease in the numbers of vessels per field in five random 
microscopic fields per tumour (mean 78 vs. 62 vessels per field, p=0.0367, Mann 
Whitney) (Figure 5.10) 
 
Figure 5.10 – Tumour Vascular Density is Decreased by mGRIN2D-Fc 
Vaccination, but not by hGRIN2D-Fc Vaccination. Haematoxylin and Eosin 
staining of excised subcutaneous CT26 tumours. 
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Chapter Conclusion 
Murine vaccination with the human form of GRIN2D precipitated only a minor specific 
IgM response with no apparent effects on angiogenesis or tumour growth in vivo. 
However, vaccination with endogenous murine GRIN2D stimulates a specific 
increase in IgG1 and IgG2b titers, indicative of a Th2 T-Cell response. Vaccination 
significantly impairs physiological angiogenesis as demonstrated by a significant 
reduction in both sponge invasion and vascular density in the subcutaneous sponge 
assay. Aside from this physiological effect, vaccination with mGRIN2D-Fc 
significantly decreases the rate of subcutaneous CT26 tumour growth. Analysis of 
the resected tumours indicates a small, but statistically significant decrease in 
vascular density within the mGRIN2D-Fc treated group, adding weight to the 
likelihood that the observed effect is due to a vascular targeted treatment. 
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CHAPTER SIX 
 
DISCUSSION 
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DISCUSSION 
The search for novel adjuvant treatments in colorectal cancer has transformed 
prognosis in a disease that was once uncontrollable if initial surgical resection was 
not successful. The ability of chemotherapy and, to some extent, radiotherapy to 
cause a reduction in tumour size has enabled both primary resection in cases 
previously deemed to be inoperable, and also systemic treatment of potential or 
observed systemic metastasis. More recently, biological agents have formed the next 
frontier in agent development, with Cetuximab, Bevacizumab, and a third monoclonal 
antibody, Panitumumab, currently licenced for use in the treatment of advanced 
colorectal cancer. However, evidence of benefit in CRC is limited, with response 
rates below 5% when used as a monotherapy (23). Development of new agents 
necessitates the identification of cell surface target proteins that are consistently 
upregulated in malignancy, but not in other body tissues. The tumour endothelium is 
hypothesised to be an effective target in malignancy, due to its relative genetic 
stability, and the ease of access from the systemic circulation in contrast to tumour 
cells(156).  
Initial efforts targeted the systemic process of angiogenesis, but this approach risks 
off-target side effects due to a lack of specificity. A number of approaches have been 
employed to identify so-called Tumour Endothelial Markers (TEMs) to achieve more 
accurate tumour vascular targeting, but the most applicable to colorectal cancer was 
the work of St. Croix et al. in 2000(53), which utilised primary isolation of endothelium 
from normal colon and colorectal cancer, followed by RNA extraction and serial 
analysis of gene expression. The original targets identified by this group (TEM1-9) 
have been open to some criticism, specifically with TEM1, or endosialin, having been 
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shown to be a contaminant from tumour associated fibroblasts and pericytes within 
the endothelially enriched compartment(157). However, it has also been shown that 
TEM1 knockout mice exhibit impaired angiogenesis in an orthotopic xenograft model 
of colorectal cancer(158). Aside from this group of endothelial targets, work following 
similar methodology within the Bicknell group has identified Robo4(159) and Clec-
14A(160) as validated tumour endothelial markers.  
 
In Chapter three, the results of further genomic analysis within the Bicknell group of 
patient-matched colorectal cancer and normal colon were explored. A systematic 
approach to validation including exhaustive literature review, subsequent validation 
on multiple biological replicates, and immunohistochemistry was completed, resulting 
in GRIN2D being identified as a putative TEM in colorectal cancer. The utilisation of 
only one further replicate to narrow the shortlist from nine to four candidates may 
have introduced inaccuracy into this process, as candidates may have been 
dismissed unfairly at this stage, should the biological replicate that was used have 
been genetically atypical of CRC. However, this fact does not affect the decision to 
pursue GRIN2D as a promising target. The lack of a specific antibody against human 
GRIN2D was severely limiting in validating GRIN2D as a target on a protein level 
through immunohistochemistry. While an endothelial pattern was observed in CRC 
with the commercially available, non-specific, antibodies, this pattern had to be 
confirmed retrospectively once a polyclonal serum was produced as part of this 
thesis. It would have been scientifically more sound to gain a reliable endothelial 
pattern before pursuing GRIN2D further. This staining pattern could also be 
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confirmed more convincingly by performing immunofluorescent co-localisation with 
an appropriate endothelial marker such as CD31. 
 
Glutamate receptors have been previously described within human cancer cell 
lines(66), and knockdown of some glutamate receptors, but not GRIN2D, has 
demonstrated variously pro- and anti-tumour effects(161). GRIN2D’s specific role in 
visceral pain perception and colonic inflammation has also been previously 
defined(64), and raises interest in GRIN2D as a protein of interest within the GI tract. 
Its predominant neonatal and embryological expression profile(60) also gives a 
logical reason as to why it may be upregulated in the proliferative microenvironment 
of a malignancy.  
 
Serum levels of glutamate have been observed to tally with Gleason grade in 
prostatic cancer(162), and noted to act as a marker of malignant potential in 
pancreatic cancer precursor lesions(163). The hypothesis linked to this latter 
observation is especially relevant to colorectal cancer, as what is proposed is that 
glutamate acts as a genetic switch which decreases the threshold of k-ras-induced 
oncogenic signalling (164). Mutation of the k-ras oncogene is a well-recognised step 
in the progression from adenoma to colorectal cancer, as discussed in Chapter one. 
 
The finding of upregulated GRIN2D expression in CRC-associated endothelium in 
Chapter four adds another level of interest to these previous studies identifying the 
significance of glutamate and its receptors within tumour cell biology. The shared 
embryonic stem cell lineage of neuronal and vascular cells is well recognised, with 
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significant cross-expression of conventionally endothelial and conventionally 
neuronal proteins observed(165). Indeed, the same processes govern modelling of 
both vascular and neuronal architecture. It is not therefore a great surprise that the 
neuronal glutamate receptor GRIN2D could also be expressed on endothelial cells. 
Also within Chapter four, it has been shown that siRNA knockdown of GRIN2D 
function in HUVEC decreases cellular migration, tube formation and chemotaxis, 
which may well be due to its role as a calcium channel component. VEGF, a potent 
and well known stimulator of angiogenesis, propagates endothelial cell migration, 
tube formation, and proliferation, at least in part, through VEGF-receptor-mediated 
calcium influx into the endothelial cell(166). It has also been shown that calcium 
influx into the cell determines VEGF-driven vascular permeability in the frog 
microvasculature(167). With reference to this point, the function of GRIN2D in 
neurons holds relevance, in that it induces a prolonged action potential compared to 
other GRIN2/3 subgroup members(168,169). It is not a great step to transfer this 
potential for prolonged intracellular calcium influx to CRC-associated endothelial 
cells, where it may offer a proliferative or survival advantage. Calcium metabolism 
also accounts for the observed anti-angiogenic effects of GRIN2D knockdown. 
Specifically, increases in free intracellular calcium concentration have been shown to 
promote cellular migration, and formation of vascular tubules in a Matrigel 
assay(170). This has been translated to assays involving the migration and 
tubulogenesis of tumor-derived endothelium, in which arachidonic acid, a potent 
inducer of intracellular calcium flux, again increased cellular migration and tube 
formation(171). There has been a call for interference in calcium metabolism to be 
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utilized in targeting tumour angiogenesis(172), and it may be that targeting of 
GRIN2D is a route to achieve this.  
 
Within Chapter three, the sequence and structure of GRIN2D was analysed, and a 
therapeutic vaccine produced. In order to be targetable by circulating antibodies, the 
antigen must be extracellular, and unique to the protein of interest, to prevent off-
target effects. The N-terminal domain of glutamate dependent NMDA receptors 
defines their function(59), and is universally considered to be extracellular, in contrast 
to the C-terminus, which is variably described as extra- or intracellular. This difficulty 
was demonstrated by the bioinformatic prediction performed to determine 
transmembrane regions, and hence extracellular regions in GRIN2D. This exercise 
demonstrated the difficulties associated with relying upon bioinformatics software for 
target design. Structure prediction sites rely upon calculations of molecular charge 
and likely intra- and inter-molecular interactions mapped to known existing structures 
of comparable sequences. They are not a substitute for protein crystallography, but 
are much more accessible and readily performed(173). These are, however, issues 
that must be allowed for when dealing with a target of interest about which there is 
little consensus regarding structure. 
 
Not only does the protein need to be unique and targetable, but it must also possess 
a secondary and tertiary structure that is likely to stimulate an immune response 
within the host. Again, bioinformatic software was utilised to determine a secondary 
structure for the extracellular N-terminus of GRIN2D, demonstrating that there were 
likely to be coiled and helical elements, increasing its chances of being immunogenic.  
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The differing immune response precipitated by the human and murine GRIN2D N-
terminus sequences are an interesting finding. Logic would dictate that immune 
reaction to a foreign protein sequence would be more established than that 
precipitated by breaking tolerance to a highly similar self-antigen. Hypothetically, it is 
also possible that the ‘foreign’ part of the human protein would be the focus of the 
immune response, with the equivalent ‘self’ segments stimulating less of a response. 
This would contrast to the full ‘self’ sequence in the case of mGRIN2D, which would 
stimulate antibodies to its full length. Psipred bioinformatic prediction of the 
secondary structure of the human and mouse GRIN2D peptide sequences ostensibly 
shows conformational homology. However, the difference in the middle section of the 
peptide sequence is potentially an interesting one: 
 
 
 
At position 37, there is a deletion within the mouse sequence of PGG - a proline and 
two glycine residues. While these residues are not particularly immunogenic in their 
own right, the absence of a proline-glycine sequence within this region may be 
omitting a ‘helix breaker’(174). Proline is a unique amino acid in that it lacks the 
amide hydrogen atom, and it is therefore unable to act as a hydrogen bond donor. 
Consequently, it does not tend to form bonds with the carbonyl group of another 
residue in the preceding turn of the helix, thereby disrupting its uniform turns(175). 
While this deletion has not indicated a specific effect in the bioinformatic structure 
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prediction that was performed, this region may well represent the reason for the 
differential in immune reactivity of the human and mouse GRIN2D components of the 
Fc-fusion proteins. The consequent lack of physiological effect observed on either 
angiogenesis or tumour growth with immunisation with hGRIN2D-Fc is likely due to 
this difference in immunogenic potential between the sequences. 
 
The creation of an Fc-fusion protein was chosen as a method to increase 
immunogenicity of the GRIN2D target sequence. This has previously been shown to 
be a successful strategy both as a result of an increased half-life of the fusion 
protein(176) and also through Fc receptor-mediated uptake by antigen-presenting 
cells such as dendritic cells(177).  
Completion of the vaccine strategy required selection of an appropriate adjuvant to 
stimulate the host immune system. Freund’s adjuvant was selected for its proven 
record, and its ability to stimulate both a Th1 and Th2 response to the co-
administered antigen, and stimulate lasting immune memory(178). This vaccine 
formulation would not be appropriate for human vaccination due to its severe local 
toxicity, and a different adjuvant strategy, such as the use of an aluminium salt, which 
is the most commonly used strategy in human vaccination. This approach has been 
successfully utilised in Robo4-Fc vaccination in the context of subcutaneous Lewis 
Lung Carcinoma tumours(135), and would represent a logical next step for GRIN2D, 
and would give increased translational impact to this work.  
 
 
!135!
The IgM predominant response triggered by hGRIN2D-Fc immunisation indicates an 
immature immune response, and results only from early differentiation of B-cells into 
plasma cells(75). Isotype switching would normally be expected if a significant 
immune response had been elicited, as was the case with mGRIN2D-Fc vaccination. 
This fact alone could explain the difference observed between the physiological 
effects of the vaccinations on both angiogenesis and tumour growth. The IgG1 
response elicited by mGRIN2D-Fc vaccination more accurately reflects a mature 
immune response, and is consistent with the presence of persisting circulating 
immune molecules to the target. This is associated with a T-helper 2-type (Th2) 
immune reaction(179), which is typical of vaccination with a protein-based 
construct(180). The concurrent IgG2b response to mGRIN2D-Fc vaccination is 
somewhat atypical, and generally is seen in vaccinations involving polysaccharide 
vaccine components(181). In this context it is more likely to represent non-specific 
activation secondary to the activation of Freund’s complete and incomplete adjuvant, 
which has been previously described(182).  
 
In this immune context, the in vivo observations of decreased physiological 
angiogenesis and decreased tumour growth described in Chapter five, alongside the 
in vitro effects of siRNA knockdown of GRIN2D in HUVEC, described in Chapter 
three, point to an antibody-mediated treatment effect on CRC endothelial cell 
function.  The specific intracellular effects of GRIN2D-Fc vaccination on endothelial 
cells has not been studied, but the upregulation of GRIN2D expression within treated 
CT26 tumour versus control Fc vaccinated mice could hold the key. This upregulation 
is likely to point to a functional impairment of GRIN2D function as opposed to a 
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targeted killing effect on endothelial calls expressing GRIN2D, in which one might 
expect to see absent GRIN2D expression in treated mice. If indeed there is a 
targeted anti-angiogenic effect from GRIN2D vaccination, it is likely that this effect 
would be systemic, and potentially persistent. It is unfortunate that the subcutaneous 
CT26 model has not been shown to be a metastatic model, as the anti-angiogenic 
effects of GRIN2D-targeting may well be relevant to metastatic spread, or indeed in 
the prevention of growth in micrometastases. Imminent future work within the group 
will translate the subcutaneous experience to an orthotopic model, and address 
these hypotheses. 
 
The murine expression profile of GRIN2D summarised in Chapter five indicates that 
in terms of endothelial expression, GRIN2D appears to be highly tumour specific. 
This specificity does not extend to bulk tissues, and treatment strategy must be 
guided by this fact. The selection of an immune strategy has been highly fortuitous 
for GRIN2D as a target, as while bulk expression in the brain is high, the blood-brain-
barrier (BBB) anatomically and physiologically prevents passage of antibodies from 
circulating microvessels into the abutting astrocytes(183). Thus, the demonstrable 
immune response against GRIN2D is limited to the endothelial compartment, 
guarding against potentially serious side-effects of brain cell death. The BBB can be 
disrupted in patients with advanced malignancy, exhibited particularly by those who 
develop brain metastases. However, spread to this site is uncommon in CRC, 
occurring in only 2-3% of cases(184). Disruption of the BBB might make targeting of 
GRIN2D in patients with known brain metastases unwise. This will prove a hurdle to 
overcome in phase two and three clinical trials, which universally focus on patients 
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with metastatic CRC, as it is here which benefit is easiest to demonstrate. Pre-clinical 
data could be presented if the brains of GRIN2D-Fc vaccinated and Fc-only 
vaccinated mice were histologically analysed to assess for the presence or otherwise 
of inflammatory infiltrates in neuronal tissues surrounding the blood vessels within 
the brain.  
 
 If the GRIN2D expression profile in humans can be considered analogous to that of 
mice, then the most important factor to consider would be the potential for 
neurological or psychiatric side effects. It has been shown that despite the 
widespread expression of GRIN2D within the developing diencephalon, a selective 
knockout mouse is able to develop normally both pre- and post-natally, including 
normal mating behaviour(185). Indeed, these mice exhibited no differences 
compared to wild-type mice in motor activity and anxiety tests, but did show reduced 
spontaneous activity measured in an open-field test.  Further characterization 
performed more recently indicated less sensitivity to stress induced by forced 
swimming tests and light-dark box models. It was therefore hypothesised that 
GRIN2D knockout mice have dysfunctional NMDA receptors and altered emotional 
behavior(186). These observations draw analogies with the glutaminergic theory of 
schizophrenia, which has been the focus of much research, summarized in 
Moghaddam and Javitt, 2012(187). This theory is based on the observations that 
agents which block NMDA-receptors, such as ketamine and phencyclidine (PCP) can 
precipitate schizoid symptomatology(188,189). However, due to the lack of 
expression in adult rodent brains(190), it has been hypothesised that GRIN2D is 
unlikely to play a major part in the pathophysiology of schizophrenia(191). Indeed, 
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recent investigations into circulating antibodies to NMDA receptor in schizophrenia 
have focused away from GRIN2D as a candidate(192), following demonstration of 
comparable expression of GRIN2D in the thalamic nuclei of schizophrenic and 
normal control human brains(193). 
Beyond the brain, expression of GRIN2D has been confirmed in the autonomic and 
enteric nervous systems(64), and unforeseen effects may occur in these sites. Based 
upon the murine expression profile, there may also be effects upon the hepatic or 
renal endothelial compartments, and any translational work should bear the 
possibility of toxicity in mind. There is clearly more translational work to be performed 
in this respect, with immunohistochemistry of human tissue arrays being the first step 
to corroborate the murine expression profile. 
Immune therapy is an established, but still rapidly expanding field within anti-cancer 
therapy, with monoclonal antibody therapy forming the bulk of approved immune 
therapies in colorectal cancer, as previously discussed. The field is constantly 
evolving, and novel applications have been described, including the use of a 
photosensitiser conjugated to an antibody specific to the Extra Domain B (EDB) of 
fibronectin, which demonstrated complete tumour ablation in a murine xenograft 
model of embryological tumour growth(194). Other groups have focused on the 
generation of chimeric antigen receptor regulatory T-cells to selectively target the 
vasculature, for instance through the targeting of VEGFR2 in multiple murine cell 
lines, including the CT26 line(195). Work has been performed to this end in colitis-
associated colorectal cancer using CEA-specific Chimeric Antigen Receptor (CAR) 
regulatory T-cells(196).  
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Vaccination based targeting of endothelial cell function offers certain benefits over 
these other novel approaches to tumour targeting, not least its potential for a relative 
lack of cost, due to the persistence of the immune response, and the avoidance of 
regular drug infusions. Having said this, evidence has also suggested that 
vaccination against a self-antigen does not result in a persistent immune response, 
with circulating antibodies returning to baseline after seven months(197), in a murine, 
Freund’s based vaccination strategy, which is not transferable to humans. It is also 
important to note that for vaccination to be a successful strategy, it requires the host 
to possess an intact immune system. This is often compromised in patients with 
malignancy, either from their malignancy itself(198), or from the effects of exogenous 
steroids(199), chemotherapeutic agents(200), opioids(201) and even the emotional 
stress brought on by a cancer diagnosis and treatment(202). Mechanisms are highly 
varied, but include T-cell mediated immunity, which may impact on the potential 
success of a pure vaccine-based treatment in this context.  
 
In terms of future work, this thesis presents just the beginning of a potentially exciting 
journey for GRIN2D. A human expression profile by means of IHC tissue array 
analysis alongside studies of potential toxicity within the murine model are 
prerequisites for moving GRIN2D forward towards clinical trials. There is also much 
work to be done to characterize the exact mode of tumour growth suppression 
demonstrated here, with exploration of whether targeting GRIN2D is interfering with 
calcium influx, leading to decreased angiogenesis and tumour growth. The animal 
models represented within this work should be taken forward not only to formulate a 
GRIN2D-based vaccine, which could be potentially usable in humans, but also to 
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apply this vaccine within an orthotopic colorectal cancer model, whereby the potential 
anti-metastatic effects of this treatment can be investigated. There is also potential 
for the use of antibody-drug conjugates in augmenting the efficacy of targeting 
GRIN2D(203), and future work could also focus upon collaborating with industry to 
this end.  
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Abstract Tumor endothelial specific expression of Robo4
in adults identifies this plasma membrane protein as an anti-
cancer target for immunotherapeutic approaches, such as
vaccination. In this report, we describe how vaccination
against Robo4 inhibits angiogenesis and tumor growth. To
break tolerance to the auto-antigen Robo4, mice were im-
munised with the extracellular domain of mouse Robo4,
fused to the Fc domain of human immunoglobulin within an
adjuvant. Vaccinated mice show a strong antibody response
to Robo4, with no objectively detectable adverse effects on
health. Robo4 vaccinated mice showed impaired fibrovas-
cular invasion and angiogenesis in a rodent sponge
implantation assay, as well as a reduced growth of implanted
syngeneic Lewis lung carcinoma. The anti-tumor effect of
Robo4 vaccination was present in CD8 deficient mice but
absent in B cell or IgG1 knockout mice, suggesting antibody
dependent cell mediated cytotoxicity as the anti-vascular/
anti-tumor mechanism. Finally, we show that an adjuvant
free soluble Robo4-carrier conjugate can retard tumor
growth in carrier primed mice. These results point to
appropriate Robo4 conjugates as potential anti-angiogenic
vaccines for cancer patients.
Keywords Immunotherapy ! Conjugate vaccines !
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